International Journal of

Molecular Sciences

Review
Psycho-Neuro-Endocrine-Immunological Basis of the Placebo
Effect: Potential Applications beyond Pain Therapy
Ángel Ortega 1 , Juan Salazar 1 , Néstor Galban 1 , Milagros Rojas 1 , Daniela Ariza 1 , Mervin Chávez-Castillo 1 ,
Manuel Nava 1 , Manuel E. Riaño-Garzón 2 , Edgar Alexis Díaz-Camargo 2 , Oscar Medina-Ortiz 3
and Valmore Bermúdez 4, *

1 Endocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia,
Maracaibo 4004, Venezuela; angelort94@gmail.com (Á.O.); juanjsv18@hotmail.com (J.S.);
nestorag17@gmail.com (N.G.); migarocafi@gmail.com (M.R.); arizathings@gmail.com (D.A.);
mervinch12@gmail.com (M.C.-C.); manuelnava93@gmail.com (M.N.)
2 Facultad de Ciencias Jurídicas y Sociales, Universidad Simón Bolívar, Cúcuta 540006, Colombia;
m.riano@unisimonbolivar.edu.co (M.E.R.-G.); e.diaz@unisimonbolivar.edu.co (E.A.D.-C.)
3 Facultad de Medicina, Universidad de Santander, Cúcuta 540003, Colombia; o.medina@unisimonbolivar.edu.co
4 Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla 080002, Colombia
* Correspondence: v.bermudez@unisimonbolivar.edu.co

Abstract: The placebo effect can be defined as the improvement of symptoms in a patient after the
administration of an innocuous substance in a context that induces expectations regarding its effects.
During recent years, it has been discovered that the placebo response not only has neurobiological



functions on analgesia, but that it is also capable of generating effects on the immune and endocrine


systems. The possible integration of changes in different systems of the organism could favor the
Citation: Ortega, Á.; Salazar, J.;
well-being of the individuals and go hand in hand with conventional treatment for multiple diseases.
Galban, N.; Rojas, M.; Ariza, D.;
In this sense, classic conditioning and setting expectations stand out as psychological mechanisms
Chávez-Castillo, M.; Nava, M.;
implicated in the placebo effect. Recent advances in neuroimaging studies suggest a relationship
Riaño-Garzón, M.E.; Díaz-Camargo,
between the placebo response and the opioid, cannabinoid, and monoaminergic systems. Likewise, a
E.A.; Medina-Ortiz, O.; et al. Psycho-
Neuro-Endocrine-Immunological
possible immune response conditioned by the placebo effect has been reported. There is evidence of
Basis of the Placebo Effect: Potential immune suppression conditioned through the insular cortex and the amygdala, with noradrenalin
Applications beyond Pain as the responsible neurotransmitter. Finally, a conditioned response in the secretion of different
Therapy. Int. J. Mol. Sci. 2022, 23, 4196. hormones has been determined in different studies; however, the molecular mechanisms involved are
https://doi.org/10.3390/ijms23084196 not entirely known. Beyond studies about its mechanism of action, the placebo effect has proved to
be useful in the clinical setting with promising results in the management of neurological, psychiatric,
Academic Editor: Alessia Ligresti and immunologic disorders. However, more research is needed to better characterize its potential
use. This review integrates current knowledge about the psycho-neuro-endocrine-immune basis of
Received: 16 March 2022
the placebo effect and its possible clinical applications.
Accepted: 4 April 2022
Published: 11 April 2022
Keywords: placebo effect; psychoneuroimmunology; conditioning; cannabinoids; opioid; hormones;
Publisher’s Note: MDPI stays neutral analgesia; pain; depression; Parkinson’s disease
with regard to jurisdictional claims in
published maps and institutional affil-
iations.

1. Introduction
In ancient times, diseases were attributed to divine punishments, and priests or
Copyright: © 2022 by the authors.
shamans would have the function of both doctors and spiritual guides. Therefore, if there
Licensee MDPI, Basel, Switzerland.
was any improvement in the health of their patients, it was not due to medicinal principles
This article is an open access article but due to “rituals”, which are now recognized as the placebo effect [1]. The first time the
distributed under the terms and word placebo (from the Latin word placēbō, complacere) was used in the medical setting
conditions of the Creative Commons was in a series of conferences dictated in 1772 by British doctor William Cullen. Since then,
Attribution (CC BY) license (https:// the meaning of this word has evolved, and it is currently defined as a substance without
creativecommons.org/licenses/by/ an active principle given to patients to improve their health or used in clinical trials to
4.0/). compare the performance of a new drug [1,2].

Int. J. Mol. Sci. 2022, 23, 4196. https://doi.org/10.3390/ijms23084196 https://www.mdpi.com/journal/ijms

Int. J. Mol. Sci. 2022, 23, 4196 2 of 22

The placebo effect can be defined as any improvement in health caused by an interven-
tion that has no direct physical-chemical effect on the ailment [3]. In modern medicine, a
placebo has been widely used as a point of comparison in clinical trials, but it was not until
the last century that the placebo effect was observed as a phenomenon in and of itself [4].
The veracity of the placebo effect was a controversial concept. Furthermore, it was
thought that if an ailment improved as a result of an inactive intervention, the ailment must
have been false from the start. However, research has demonstrated that the placebo effect
is a real phenomenon [1,4,5]. While it is not a miraculous cure for diseases, it can alleviate
a wide number of symptoms, such as pain [6], anxiety [7], bradykinesia [8], and improve
the physical [9] and cognitive [10] performance of completely healthy individuals. This is
achieved through interventions that have different degrees of complexity, which can go
from the white coat of a doctor—which provides the patient a feeling of trust and positive
expectations [10,11]—to the administration of inactive drugs [12] and the performance of
ancient rituals [13].
The effects of placebos have been hypothesized as caused by the integration of psycho-
logical, neurological, endocrine, and immune changes, which overall favor the well-being
of individuals and could go hand in hand with the conventional treatment of multiple
diseases [5], which is the axis of its clinical importance. Therefore, the goal of this narrative
review is to describe the psycho-neuro-endocrine-immune (PNEI) basis of the placebo
effect and its possible clinical applications.

2. Psycho-Neuro-Endocrine-Immune Basis of the Placebo Effect

During the last years, clinical use of the placebo effect has led to the development of
different hypotheses regarding the molecular basis involved in its mechanism of action.
Mainly, it has been discovered that is capable of generating psychological, neurobiological,
immune and endocrine effects (Figure 1). In the following sections, we discuss the PNEI
molecular mechanisms of the placebo effect.

Figure 1. Psycho-neuro-endocrine-immune mechanisms of the placebo effect. The administration

of a placebo generates a series of psychological and physiological changes in an individual. From
the psychological standpoint, it can cause expectations or work as a conditioned stimulus. This is
transmitted at the neurological level through an increase in the neurotransmission of µ opioid
Int. J. Mol. Sci. 2022, 23, 4196 3 of 22

receptors in the rostral, pre and subgenual anterior cingulate cortex, the prefrontal dorsolateral
cortex, the orbitofrontal cortex, the anterior insular cortex, the nucleus accumbens, the amygdala, the
thalamus, and the periaqueductal substantia nigra. This mechanism is involved in placebo-mediated
analgesia and anxiolytic responses. Likewise, there is an increase in the transmission of the CB1
cannabinoid receptor in placebo analgesia conditioned with non-opioid mechanisms and an increase
in dopaminergic transmission in PD patients treated with placebos, leading to clinical improvement.
On the other hand, the close communication between the CNS and the immune system allows
for conditioned immune suppression. In this mechanism, the insulate cortex, the amygdala, the
sympathetic nervous system as the main efferent pathway, and noradrenaline as the neurotransmitter
responsible for immune suppression are involved. Likewise, a conditioned response in different
components of the endocrine system has been observed. However, the mechanisms mediating this
have not been described yet. PD: Parkinson’s disease.

2.1. Psychological Mechanisms: The Power of the Mind

Different psychological mechanisms are involved in the placebo effect. Among these,
are expectations, learning, memory, and motivation. While there is growing research in-
volving these mechanisms, the most studied and supported ones by experimental evidence
are classic conditioning and expectations [14].
Physical conditioning is the creation of a connection between a new stimulus and an
already existing reflex. Therefore, it is a type of learning in which an originally neutral
stimulus causes a reaction thanks to the association of this stimulus with the one that
normally leads to said response [15]. Conditioned stimuli in the placebo effect arise from
the clinical setting [16,17], and the answers to the placebo are not limited to “inactive”
interventions. Treatments with effective active ingredients also function as a conditioned
stimulus, so in addition to having therapeutic effects based on their inherent pharmacologi-
cal properties, they can generate a placebo response that improves the therapeutic benefit
of the treatment [17].
It is also important to highlight the implications of the doctor–patient relationship
in the psychological mechanisms of the placebo effect. It has been demonstrated that
explicit verbal information can increase the efficacy of the placebo effect in conditioned
analgesia [18]. On the other hand, the transference phenomenon, which is the tendency
of the patient to see the doctor as an important person from their past [19], is related to
classical conditioning [20] and it generates expectations.
Expectations are what the patient believes they will experience with a treatment,
and it has been proven that they have a transcendental impact on what is perceived.
When the patient consciously expects a positive result based on elements such as verbal
instructions, previous experiences, and emotional changes, among others, this leads to
internal changes that determine specific beneficial experiences [21,22]. Wanting to get better
is another psychological aspect that could directly interact with expectations and amplify
or reduce the placebo effect, as well as emotions. However, this has been studied to a lesser
degree [23].

2.2. Neurobiological Mechanisms Underlying Placebo Effects

Thanks to advances in neuroimaging studies, it has been possible to identify the areas
of the brain involved in the mechanisms of the placebo effect. Similarly, the neurotransmit-
ters responsible for this phenomenon have been described, demonstrating that there are
different neurobiological pathways involved in this effect [5].
The most widely described placebo effect is placebo analgesia. Therefore, this type
of placebo has been used as the main model to describe the neurobiological mechanisms
involved in this phenomenon. When a painful stimulus is received, the nociceptive sig-
nal ascends through the nervous fibers of the spinal cord, reaching different parts of the
encephalon such as the periaqueductal grey substance, the hypothalamus, the thalamic
nuclei, the amygdala, and the rostral anterior cingulate cortex [24]. In individuals respon-
sive to placebos, the activity of these regions was reduced with the administration of a
Int. J. Mol. Sci. 2022, 23, 4196 4 of 22

placebo, and an increase in functional connectivity between the rostral anterior cingulate
cortex and the brain stem was observed [25–27]. Similarly, due to the expectation caused
by the context of the placebo, an increase in the activity of the prefrontal cortex and the
nucleus accumbens was observed [5,25,27,28]. These areas play a fundamental role in the
integration of emotion/motivation, cognition, reward, and learning [29,30]. Therefore,
they are instrumental for the placebo effect and it has even been reported that temporary
interruption of the functionality of the prefrontal cortex through magnetic transcranial
stimulation can completely block placebo analgesia [31].
These circuits are involved in affective and motivational states; therefore, the anti-
anxiety and antidepressant effects of placebos are mediated by the same brain regions
involved in analgesia. Mainly, these include the amygdala, the orbitofrontal cortex, and the
dorsal cingulate cortex [32,33], which have important roles in the development of emotions,
memory, and fear management, among others.

2.2.1. Role of Opioids

In the context of neurotransmitters, placebo analgesia is mediated mainly by the
endogenous opioid system. Opioids are a group of drugs that have been heavily used
throughout history for analgesia purposes [34,35]. In 1975, encephalins were discovered,
becoming the first endogenous opioid peptides [36]. Since then, β-endorphins [37], en-
domorphins [38], and dynorphins [39] have been discovered. All these are endogenous
ligands of opioid receptors, which are transmembrane proteins coupled to G proteins
divided into three groups: mu (µ) [40], delta (δ) [41], and kappa (κ) opioid receptors [42].
These are distributed in the peripheral and central nervous system (CNS) [42], in immune
cells such as lymphocytes and macrophages, in the suprarenal glands, the heart, the liver,
the lungs, and the kidneys [43].
The type of receptor (µ, δ, κ) leads to a different response once an opioid couples to it,
with the α subunit of the G protein exchanging its GDP molecule for GTP. The α-GTP and
βγ subunits dissociate and interact with target proteins. Classic opioid agonists lead to the
inhibition of adenylate cyclase, causing a decrease in the levels of cAMP, an increase in K+
conduction, and a decrease in Ca++ conduction. This causes the hyperpolarization of the
cell and, in the case of neurons, a decrease in neurotransmitter secretion [44].
Likewise, opioids lead to a decrease in both the neuronal excitation of the dorsal root
ganglia of the spinal cord as well as the excitatory postsynaptic currents produced by
glutamate in the spinal cord. This results in a reduction in the transmission of nociceptive
stimuli, and therefore, decreased perception of pain [45].
The first evidence of the involvement of the opioid system in the placebo effect
emerged from a study performed by Levine et al. in 1978. It included a sample of 27 men
and 24 women aged between late adolescence and 30 years of age who underwent extraction
of the third mandibular molar. It was concluded that the administration of antagonists of
opioid receptors µ can inhibit placebo analgesia in post-operatory pain [46,47]. Later studies
showed an increase in β-endorphins in the cerebrospinal fluid (CSF) of patients responsive
to placebos [48] and demonstrated that placebo analgesia is mediated exclusively by µ, as
selective inhibitors of δ and κ receptors did not decrease the placebo effect [49]. In addition,
genetic analyses suggest that the polymorphism of the mu opioid receptor gene (OPRM1)
are directly involved in the interindividual variation seen in placebo analgesia [50].
Likewise, the use of positron emission tomography (PET) with [11C]carfentanyl as a
marker has led to discovering which CNS regions show an increase in neurotransmission
mediated by µ opioid receptors caused by the administration of placebo with analgesia
expectations. Among these regions are the pre- and subgenual rostral anterior cingulate cor-
tex [47,51–54], the dorsolateral prefrontal cortex [51,53,54], the orbitofrontal cortex [52,54],
the anterior insular cortex [51–54], the nucleus accumbens [51–53], the amygdala [52–54],
the thalamus [53,54], and the grey periaqueductal substance [52,53]. These regions of the
brain are associated with pain modulation, emotions, and the brain reward system. Further-
more, studies have shown spinal nociception inhibition as part of placebo analgesia [55].
Int. J. Mol. Sci. 2022, 23, 4196 5 of 22

Although the antinociceptive opioid system is the most widely documented, it is

not the only one. It has been observed that despite the administration of naloxone, an
antagonist of opioid receptors, placebo analgesia can still exist in certain circumstances [56].
This has been shown in an experimental study performed by Vase et al. in 2005 in a sample
of 26 female patients with irritable bowel syndrome (IBS). These were divided into two
groups, with one group receiving saline IV solution and the other one receiving naloxone.
At the same time, they received rectal lidocaine (RL), rectal placebo (RP), or no intervention
(natural history, NH) during three sessions that took place on different days. The results
showed that, compared with NH, pain classifications were significantly lower with the
administration of RL or RP. However, there was no significant difference between RL and
RP. Similarly, the result was the same in the group with saline solution and the naloxone
group, suggesting that the placebo effect was not mediated by opioids in this case [57].
This sets the basis for the hypothesis that different stimuli can cause different types
of placebo effect, and that analgesia placebo can be produced by opioid and non-opioid
mechanisms [16,58]. These last ones have not been as widely studied; however, evidence
suggests that they are mainly mediated by the endocannabinoid [56] and dopaminergic
systems [59].

2.2.2. Endocannabinoid System

The elements that form the endocannabinoid system are cannabinoid (CB) receptors
coupled to protein G, which are CB1—particularly abundant in the brain cortex, amygdala,
basal ganglia, hippocampus, and cerebellum [60]—and CB2 which is mainly present in
the microglia and vascular elements [61]; its endogenous ligands, which are anandamide
(arachidonoyl ethanolamide) and 2-arachidonoyl glycerol; the enzymes that synthesize
these ligands (Phospholipase D, specific to N-acylphosphatidylethanolamine, and dia-
cylglycerol lipase α); and degrading enzymes (fatty acid amide hydrolase (FAHH) and
monoacylglycerol lipase). These components are present in the periphery as well as cen-
tral areas of the nociceptive pathway. Endocannabinoids have antinociceptive effects in
neuronal circuits through the retrograde transmission of CB1 presynaptic transmitters [62].
The participation of endocannabinoids in placebo analgesia has been demonstrated
when non-opioid drugs are administered and these are later replaced by a placebo and when
antinociceptive effects are not completely reversible with naloxone [56,58]. Furthermore,
the CB1 receptor antagonist, rimonabant, completely suppresses placebo analgesia [63].
Likewise, it has been proven that homozygotes FAAH Pro129/Pro129, which is the FAAH
coding gene for the first endocannabinoid-degrading enzyme, resulted in higher placebo
analgesia effects and mediate more positive affective states as well during the 24 h after the
administration of the placebo [64]. An explanation for this could be that high concentrations
of endocannabinoids cause desensitization of the CB1 receptor [65].

2.2.3. Dopaminergic System

The dopaminergic system is formed by dopamine, a catecholaminergic neurotrans-
mitter mainly synthesized in the central nervous system, especially in the substantia nigra,
and the dopamine receptors. These differentiate into five subtypes (D1, D2, D3, D4, and
D5) and they are coupled to G proteins. The receptors mediate all dopamine physiological
functions. Among these functions are motor regulation, motivation, excitation, reward,
cognitive function, pleasure, sexual behavior, breastfeeding, and nausea [66].
Dopamine cannot be classified only as an excitatory or inhibitory neurotransmitter as
this will depend on the intervening receptor, second messenger response, the activation
of the ion channel on the postsynaptic plasmatic membrane, and protein expression pro-
files [67]. Dopamine receptors are classified into type D1 receptors (D1 and D5), which are
coupled to Gαs proteins that stimulate the production of cAMP through the activation of
the adenyl cyclase enzyme; and type D2 receptors (D2, D3, and D4), which are coupled to
Gαi, which inhibits cAMP production. In addition to cAMP regulation, dopamine recep-
Int. J. Mol. Sci. 2022, 23, 4196 6 of 22

tors can have biological effects through alternative signaling pathways, such as regulating
calcium channels and Na+ /K+ ATPase through direct protein–protein interaction [68].
Different authors have linked the mesolimbic system, which is one of the main
dopaminergic circuits, to placebo analgesia, mainly in reward anticipation. Dopamine
release can mediate the analgesic effects of some placebos by decreasing activity in regions
sensitive to pain, including the thalamus, insula, the anterior cingulate cortex [11,69,70],
and the ventrolateral prefrontal cortex [71].
An important aspect of dopamine is that it can participate in different placebo effects,
not only analgesia, as its mechanism of action is related to expectations. Therefore, it
can intervene in a great number of conditions. For example, the expectation of caffeine
consumption causes dopaminergic placebo effects similar to those seen in people who
have received oral caffeine [72]. Most studies evaluating the implications of dopaminergic
pathways are not focused on analgesia, but on the improvement of clinical symptoms
caused by placebo effects in patients with Parkinson’s Disease (PD).
Motor difficulty in PD patients is caused by a decrease in dopamine release by
dopaminergic neurons in the substantia nigra and the striatum as well as by the death of
these neurons [73]. The benefits of the placebo effect in PD arise from the activation of
the damaged nigrostriatal dopaminergic system as well as the mesolimbic pathway. PET
studies used the coupling of [11 C] raclopride (RAC) to the D2/D3 dopamine receptors as
an index of dopamine activity, showing that the administration of placebo in PD patients
increased the release of dopamine in the dorsal striatum (caudate and putamen nuclei),
especially in those responsive to placebos. This was also observed in the ventral striatum
(accumbens nucleus), although no differences were observed between subjects responsive
to placebos and those who were not responsive. Therefore, it was concluded that dopamine
release in the ventral striatum is due to reward expectation and not the reward itself [74–76].
Likewise, dopamine release was larger in patients that were told they had a 75%
chance of receiving the real treatment compared with those that were informed of a lower
percentage (25%, 50%), and even those informed of a larger percentage (100%). Therefore,
there is a possibility that uncertainty also plays a role in dopamine release caused by the
placebo effect [77,78]. Different researchers have reported that placebos could possibly
generate addiction in individuals who consume them, although the mechanisms that lead
to dependence remain unknown [79,80].
In opposition to the previously described mechanisms, cholecystokinins (CCK) are
inhibited by the placebo effect, and even proglumide, an antagonist of CCK-1 and CCK-2
receptors, can potentiate the placebo effect. It can also inhibit nocebo hyperalgesia, showing
that CCK acts as a counterpart to the opioid system [16].

2.2.4. Other Neurotransmitters

The aforementioned neurotransmitters might not be the only ones involved in the
placebo effect. A double-blind experimental study performed by Kessner et al. in 2013
evaluated a sample of 80 healthy young men. They were injected with either oxytocin or
saline solution before applying an inactive cream with expectations of analgesia. It was
observed that the administration of oxytocin could improve placebo analgesia. It was
hypothesized that this result was due to the effects of trust and empathy induction by
oxytocin, leading to an increase in credibility regarding the instructions provided by the
medical personnel to the participants [81]. However, a more recent study performed by
Skvortsova et al. in 2018 with a sample of 108 healthy women between 18 and 35 years of
age contradicted this discovery. There was no effect reported for oxytocin in the context of
the placebo effect [82]. The greater limitation of these studies is that they did not have a
representative population sample, being exclusively centered on the effect of oxytocin in
just one sex.
An experimental study performed by Colloca et al. in 2016 with a sample of 109 individuals
(59 women and 50 men) associated the administration of vasopressin with an increase in
placebo analgesia, although this finding was observed mainly in women [83]. This study
Int. J. Mol. Sci. 2022, 23, 4196 7 of 22

did not find an association between oxytocin and the placebo effect, but researchers point
out that this could be caused by the doses of oxytocin administered, which were lower than
those used in the research performed by Kessner et al. (24 vs. 41 IU, respectively) [83]. In
both cases, research has been scarce and the results have been contradictory. Therefore, the
participation of these hormones in the placebo effect is not entirely understood.

2.3. Immunological Mechanisms

It is currently known that important communication takes place between the nervous
and the immune systems [84]. An example of this is the regulation of the immune response
at a cellular and humoral level, mediated by neurological phenomena such as stress [85–87].
Likewise, it has been reported that the activation of the immune system can modify
neurologic characteristics, such as mood, behavior, and anxiety levels [88].
Afferent and efferent pathways in this interaction are formed by neuronal and humoral
mechanisms (Figure 2). In the case of the efferent pathways, the neural component is
represented by the vagus nerve, representing the parasympathetic branch of the autonomic
nervous system [89], and the sympathetic nervous system, which provides innervation
to primary and secondary lymphoid organs and releases catecholamines, with receptors
expressed by leucocytes [90]. Likewise, the humoral factor could be represented by the
Hypothalamus–Pituitary–Adrenal (HPA) axis through the release of cortisol [87]. On the
other hand, afferent pathways would have the vagus nerve as the neural component [89,91]
and cytokines and prostaglandins as the humoral factors as these cross the Blood–Brain
Barrier (BBB) [92,93].

Figure 2. Pathways of neurommunological integration. Afferent and efferent pathways have a neural
and a humoral component. The sympathetic nervous system innervates the primary and secondary
lymphoid organs. The vagus nerve, which is part of the parasympathetic autonomic nervous system,
has both afferent and efferent neurons, participating in both pathways. Cytokines can cross the
blood–brain barrier and the hypothalamus–hypophysis–adrenal axis is responsible for humoral
efference. ACTH: Adrenocorticotropic hormone; CRH: Corticotropin-releasing hormone.

This interaction between the CNS and the immune system makes it possible for
the placebo effect to influence immune responses. In fact, it has been reported that the
administration of a placebo for pain relief can reduce the levels of interleukin (IL)-18, a
proinflammatory cytokine. IL-8 decrease is mediated by the placebo-induced release of
endogenous opioids induced in the left nucleus accumbens [94].
Int. J. Mol. Sci. 2022, 23, 4196 8 of 22

However, some studies have observed that expectation alone is not capable of gen-
erating significant immunomodulation [95], for which a conditioned immune response
must exist, where pavlovian learning is used to “teach” the immune system to act in a
specific way when a placebo is administered [96]. This type of placebo effect can produce
conditioned immunosuppression, where the sympathetic nervous system acts as the main
efferent pathway [97,98] and norepinephrine acts as the neurotransmitter responsible for
immunosuppression. This is suggested by the fact that propranolol, a β-adrenergic receptor
antagonist, completely reverses this immunosuppressive effect [99,100].
Besides this, the immunosuppression conditioned with cyclosporine A is mainly
mediated by the insular cortex and the amygdala, which are activated by the direct action
of cyclosporine A in the brain through a mechanism that is still unknown, but is different
from vagal afferents [101], causing a reduction in the expression and production of mRNA
for IL-2, interferon-γ (IFN-γ) and T-cell proliferation [102].
This conditioned immune response can be remembered by both animal and human
models [103], which was demonstrated in 2018 by Kirchhof et al. who observed conditioned
immunosuppression in a sample of 30 kidney transplant patients (24 men and 6 women).
This experiment took place during three phases. First, the baseline, where cyclosporine
A and tacrolimus were administered as immunosuppressants to the patients and blood
was extracted to analyze immune and neuroendocrine parameters. Second, the acquisi-
tion phase, in which patients received cyclosporine A, tacrolimus, and a novel gustatory
stimulus serving as conditioned stimulus. Third, the evocative phase in which the adminis-
tration of the immunosuppressant drug was alternated with the placebo, administering
both with the green tastebud stimulant. The results of this study showed conditioned
immune suppression, reflected by the inhibition of T lymphocytes when a placebo was
administered instead of cyclosporine A and tacrolimus [104]. Similar results have been
observed in numerous rodent studies [105].
Different experimental studies have attempted to reproduce conditioned immunos-
timulation, such as the studies by Buske-Kirschbaum et al. from 1992 and 1994, in which
epinephrin conditioning (non-conditioned stimulus) and a neutral sorbet sweet (condi-
tioned stimulus) increased the activity of natural killer (NK) cells [106,107]. However, this
effect was not achieved in other reports, such as the one published by Grigoleit et al., a study
in which conditioning with lipopolysaccharides (LPS) was attempted (non-conditioned
stimulus) and a beverage with a characteristic flavor (conditioned stimulus) was provided
without observing any increase in the plasma concentrations of IL-6 and IL-10, Tumoral
Necrosis Factor (TNF) α, or a significant increase in body temperature once the placebo
was administered, which differed from when the individuals were exposed to LPS [108].
Despite advances in the understanding of placebo immunomodulation, the precise mecha-
nisms involved in this phenomenon are not fully understood, highlighting the importance
of continued studies in this area.

2.4. Endocrine Mechanisms: Placebo Effect on Hormone Secretion

Hormone secretion is a process intrinsically involved in the physiologic mechanisms
of multiple organ systems. Therefore, its dysregulation is a cornerstone of endocrine
disorders such as diabetes mellitus, thyroid disease, and adrenal insufficiency, among
others [5,109]. Hormone secretion can be defined as an unconditioned response to different
non-conditioned stimuli; likewise, stimuli that take place with the non-conditioned stimulus
can be associated with hormonal responses and become a conditioned stimulus. Drug
consumption and the environment of the administration of a drug are one example of
this [74,88]. Therefore, the use of endocrine conditioning to control hormone levels through
conduct manipulation could have important clinical implications.
The effects of the application of classic conditioning have been widely studied in
the endocrine system in animal and human models [109–112]. Studies have reported di-
verse conditioned responses depending on the non-conditioned stimuli used. Conditioned
changes in corticosterone and cortisol are among the most widely researched in animal
Int. J. Mol. Sci. 2022, 23, 4196 9 of 22

models [111–115]. A large proportion of these studies show significant changes in corti-
costerone or cortisol levels after conditioning. Barreto et al. [111] reported feeding as a
non-conditioned stimulus, which led to a conditioned cortisol increase in Nile tilapia fish.
Similar findings were reported by Ader et al. [112] in a study in which an increase
in conditioned corticosterone took place after the administration of cyclophosphamide
as a non-conditioned stimulus. On the other hand, Coover et al. [109] reported food as
a non-conditioned stimulus that led to a conditioned decrease in corticosterone. Similar
to animal models, human assays analyzed the conditioned responses to cortisol, finding
contradictory results between them. Sabbioni et al. [114] and Hall et al. [113] reported
a significant cortisol increase, while Benedetti et al. [110] observed a decrease in cortisol
levels and Stockhorst et al. [116] did not find significant results.
After cortisol and corticosterone, the conditioned release of insulin has been the most
widely described response in pre-clinical and clinical settings [116–121]. Detke et al. [117]
and Roozendaal et al. [118] found a significant increase in insulin levels in mice. At the
clinical level, two studies performed by Stockhorst et al. [119,120] demonstrated condi-
tioned increases of insulin in humans, using as the non-conditioned stimuli intravenous
insulin and intranasal insulin, while other reports did not find significant changes in insulin
levels [119,121].
Additional studies in animal models have evaluated the release of other hormones
as a response to placebo. Onaka et al. [122] and Tancin et al. [123] showed a signifi-
cant increase in the release of conditioned oxytocin. Similarly, Graham et al. [124] and
Golombek et al. [125] demonstrated the conditioned release of testosterone, luteinizing
hormone, and melatonin in mice. However, due to the scarcity of assays evaluating these
hormones, more studies are necessary to replicate and confirm these findings. Finally,
there are other studies at the clinical level that have evaluated the placebo effect with
certain hormones without animal models. Benedetti et al. [110] and Stockhorst et al. [119]
reported significant increases in growth hormone levels through classic conditioning. On
the other hand, other human studies have failed to demonstrate a conditioned release of
glucagon [116,119].
Despite the findings regarding conditioned responses in different components of the
endocrine system, the majority of studies have certain limitations. The most remarkable
one is the fact that the majority of assays were performed in men, without considering the
possible moderation of the conditioned response according to gender. Therefore, future
research should consider gender specificity in endocrine responses as well as evaluate other
endocrine parameters that have not been entirely explored. The main human studies of the
placebo effect are summarized according to the underlying mechanism in Table 1.

Table 1. Psycho-neuro-endocrine-immune mechanisms of the placebo effect.

Authors (REF) Mechanism Methodology Results

Thirty-four healthy subjects were divided A decrease in pain classification
into two groups. Both received stimulation (p < 0.05) and the amplitude of LEP
with a CO2 laser and a conditioning (p < 0.01) in response to the signals was
procedure through which two visual signals reported only in the group that received
Carlino et al. were coupled with increases and decreases in verbal information. This suggests that
Psychological
[18] the strength of the stimulus. However, one the visual–analgesic association does not
group was verbally informed about the happen without explicit verbal
meaning of the keys and the second group information. This highlights the
was blinded. The LEP was used as the importance of cognitive content as
response index. context to the keys.
Int. J. Mol. Sci. 2022, 23, 4196 10 of 22

Table 1. Cont.

Authors (REF) Mechanism Methodology Results

When the placebo group was divided
A double-blind study included 51 patients
into responsive and non-responsive, it
who underwent extraction of their third
was observed that naloxone
molar. The patients were distributed in
Levine et al. Neurobiological administration increased pain scores
groups to administer morphine, naloxone, or
[46] (Opioids) only in responders. This suggests that
placebo in a different order. Two pain
the analgesic effect of placebo is
classification scales were used. One was
reversible with naloxone as this is an
visual and the second was verbal.
antagonist of µ opioid receptors.
The effects of rimonabant (CB1 receptor It was observed that in the group who
antagonist) as an inhibitor of the placebo received initial placebo analgesia,
effect were evaluated in 82 volunteers, who rimonabant blocked the placebo
Benedetti et al. Neurobiological underwent a pain test with a tourniquet for response entirely. Likewise, a
[63] (Endocannabinoids) five consecutive dates. Patients were divided statistically significant difference was
into six groups to receive different observed for pain tolerance in the
combinations of placebo, pain killers, placebo group with rimonabant and the
and rimonabant. placebo without rimonabant (p < 0.001).
The results of the patients before and
The release of endogenous dopamine caused
after receiving the placebo were
by the placebo effect in patients with PD was
De la Fuente- compared. A significant decrease was
Neurobiological measured through PET. It was estimated
Fernández et al. found in the coupling potential of
(Dopamine) according to the competition between
[74] striatum RAC of 17% in the caudate
endogenous dopamine and RAC to couple to
nucleus and 19% in the putamen
D2-D3 receptors.
(p < 0.005 for both).
Immunologic functions and basal
On day two of the evocative phase,
neuroendocrine parameters were analyzed in
decreases in the proliferative capacity of
30 patients. They had all had kidney
T cells (p < 0.001), in the expression of
transplants and had been prescribed immune
Kirchhof et al. γ-IFN mRNA (p = 0.05) and of cortisol
Immunological suppressant drugs. Afterward, the drug was
[104] circadian plasma levels (p < 0.05) were
administered together with a gustative CS
reported. However, there were no
(acquisitive) and finally, some doses were
changes in the number of T cells or in
given with a placebo and the gustative
the levels of IL-2 and catecholamines.
CS (evocative).
In a double-blind study, 25 healthy men were
divided into two groups. During the first
phase, one group received placebo capsules It was observed that the experimental
(control) while the second one received a group had significantly higher cortisol
Sabbioni et al.
Endocrine beverage with a distinct flavor and plasma levels when they received the
[114]
dexamethasone capsules (experimental). beverage and the placebo capsule
During the second phase, all subjects (p = 0.015).
received a beverage and a placebo capsule
every other day.
A double-blind assay evaluated 32 healthy
On day 2, the levels of peripheric insulin
men who were divided into two groups. On
increased in group 1 and decreased in
day 1, the first group received intranasal
group 2 (p = 0.027). While the glycemic
Stockhorst et al. insulin together with an olfactory CS while
Endocrine levels decreased in group 1 and
[120] the second group received a placebo together
increased in group 2, there was no
with the CS. On day 2, both groups received
statistically significant difference
a placebo and CS. The evaluated variables
(p = 0.150).
were glycemia and insulin levels.
Abbreviations: LEP: N2-P2 component of laser-evoked potentials; PET: Positron emission tomography; RAC: [11C]
racloprida; CS: Conditioned stimulus; UCS: unconditioned stimulus.

3. Preclinical and Clinical Implications of the Placebo Effect

During the last decade, there have been significant advances in the development
of preclinical evidence regarding the placebo response, with the main goal of creating
reproducible animal models that would bring great advantages to this field. Among these,
Int. J. Mol. Sci. 2022, 23, 4196 11 of 22

there are advances in molecular mechanisms involved in the placebo response as well as
experimental manipulations that cannot be performed in humans for technical or ethical
reasons [126].
The current discussion about ethical considerations is based on aspects related to
deceptive placebos and placebos without deception [127]. The first is the one that has
been more extensively prohibited according to international ethical guidelines, mainly
under the policy emitted by the American Medical Association in which it is declared that
“Doctors can use placebos for diagnosis or treatment only if the patient is informed and
accepts its use” [128]. On the other hand, a considerable number of research studies about
placebos without deception have questioned the widely shared assumption that placebos
require deception to be effective. Usually, in this type of study, denominated “open-label
placebo”, individuals are assigned to either a group that does not receive treatment or
another group that will receive a placebo pill [129]. Furthermore, patients are informed of
the fact that the pill does not have any active medication and the researchers read a script to
the patient informing them about placebo response and explaining the justification for the
study. Recently, this methodology has provided information about statistically significant
improvements in patients with chronic lumbar pain [130], IBS [131], depression [132], and
recurrent migraines [133]. It has been suggested that administering placebo medication can
have beneficial effects even if it is not deceptively presented as an efficient treatment.
A new type of treatment protocol has been applied in the open-label placebo model
called pharmaco-conditioning to resolve possible ethical implications. In this therapeutic
regime, an open-label placebo is coupled with an active drug until the administration of
the open-label placebo alone induces a conditioned placebo response. The effectiveness
found in different studies [134,135] suggests that this method can be effective to maintain
the therapeutic response while the secondary effects of active drugs decrease. This could
be a less controversial way to incorporate placebos in the clinical setting.
Currently, the available clinical evidence regarding the placebo effect is extensive and
variable, especially in the case of neurologic, psychiatric, and immune disorders. The next
section summarizes the key clinical evidence regarding the impact of the placebo effect as
treatment for these disorders (Table 2).

Table 2. Clinical evidence of the placebo effect.

Authors (REF) Disorder Methodology Results

A randomized, controlled, open-label study Greater pain reduction was observed in
included 83 patients who had chronic lumbar each of the scales in the patients who
pain for less than three months. They received a placebo in comparison to
Carvalho et al. Neurological randomly received either two tablets of those receiving their usual treatment
[130] (Pain) placebo a day or their usual treatment for (p < 0.001). Similarly, those treated with
three weeks. The intensity of the pain was a placebo had a reduction in their
measured through three scales and a total disability compared to those in their
score was obtained. regular treatment (p < 0.001).
A Phase III, randomized, placebo-controlled,
The placebo significantly delayed the
double-blind trial evaluating the use of
time to progression (p = 0.02). Likewise,
beta-1a interferon included 301 patients with
Jacobs et al. Neurological patients had fewer exacerbations
multiple sclerosis. Time to progression of
[136] (Multiple sclerosis) (p = 0.03) and fewer and smaller brain
disability was the primary endpoint,
lesions in magnetic resonance imaging
measured using the Expanded Disability
(MRI) (p = 0.02).
State Scale from Kurtzke.
An open-label, placebo-controlled study There were no statistically significant
included outpatient individuals who were differences between groups (p = 0.26).
Kelley et al. Psychiatric
diagnosed with major depressive disorder. However, improvement before and after
[132] (Depression)
They were randomized into a control group four weeks of receiving the placebo was
and an open-label placebo group. observed (p = 0.03).
Int. J. Mol. Sci. 2022, 23, 4196 12 of 22

Table 2. Cont.

Authors (REF) Disorder Methodology Results

The results according to the LSAS-SR
A trial evaluated 46 patients diagnosed with
were better in the open-label group than
social anxiety, randomizing them to receive
the blinded group (p < 0.0001), with a
Faria et al. Psychiatric nine weeks of open or blinded treatment
response rate three times higher
[137] (Anxiety) with escitalopram. The efficacy of the
(50% vs. 14%; p = 0.009). This was
treatment was evaluated with the LSAS-SR
correlated with greater activity of the
and brain activity measured through MRI.
posterior cingulate gyrus (p = 0.0006).
Thirty patients with allergic rhinitis received
a beverage with a distinct flavor followed by The water group had a decrease in
a dose of desloratadine for five consecutive symptoms and results of the cutaneous
days. Afterward, 10 patients received water test but not in basophil activation. The
Goebel et al. Immunological
together with a placebo pill (water group), placebo group had a decrease in
[138] (Allergic rhinitis)
11 patients were exposed again to the basophils, decreased response in the
beverage and the placebo pill (placebo cutaneous test and symptoms similar to
group) and nine patients received water and those observed in the drug group.
desloratadine (drug group).
Abbreviations: LSAS-SR: self-rated Liebowitz Social Anxiety Scale.

3.1. Neurological Disorders

The placebo effect has been reported to possibly improve various neurological disor-
ders. In this sense, the use of classical conditioning for the induction of analgesia has been
extensively studied in the last 20 years. The first attempts to materialize placebo analgesia
in mice led to authors reporting that taste and olfactory stimuli coupled with morphine as a
conditioned stimulus caused analgesia in mice [139–141]. Afterward, it was demonstrated
that tactile and visual stimuli coupled with the administration of morphine as a conditioned
stimulus can generate placebo analgesia in female mice [58]. Zhang et al. [49] were able
to replicate the results in Sprague–Dawley male rats. On the other hand, Lee et al. [59]
recently proposed a new animal model of placebo analgesia. In their study, they used a
conditioning paradigm in which a neutral signal was conditioned to different pain intensi-
ties in an attempt to avoid the possible stress associated with analgesia injections during
conditioning phases. The authors found that in this drug-free conditioning process, there
was a decrease in the nociceptive response to heat in which animals learned to associate
their conditioned space with lower exposure to heat. However, studies with a larger sample
and more rigorous analyses that replicate these findings are needed to determine if it is a
reliable method to cause placebo analgesia in mice.
The majority of preclinical studies have been mainly based on acute pain models, with
only three published animal assays attempting to examine placebo analgesia in chronic
pain [142–144]. First, McNabb et al. [143] evaluated placebo analgesia in female mice
who received a spinal clamping of the L5 nerve to induce a condition of neuropathic
pain. Contextual stimuli such as the environment, time, smell, touch, and sight were
used as conditioning stimuli; however, no significant differences were found. Alternatively,
Zeng et al. [144] reported the induction of pharmacologically conditioned placebo analgesia
using a model of spinal nerve clamping. However, this study did not include proper control
groups to separate the effects of placebo from the non-specific responses that can be caused
by other factors. More recently, Akintola et al. [142] approached these limitations in a
rodent model of neuropathic chronic pain, finding that chronic pain in mice could be
non-responsive to placebo analgesia.
Beyond the numerous studies in animals, classic conditioning has also been proven as
an analgesic in humans in different pathologies associated with pain [145–149]. Multiple
meta-analyses from clinical studies report a weak therapeutic effect on central neuropathic
pain [148] and the complex regional pain syndrome, and a moderate effect in postherpetic
neuralgia [150], peripheral diabetic neuropathy [150], VIH associated pain [150], fibromyal-
gia [151], and migraines [146,147,152]. On the other hand, only three open-label place
Int. J. Mol. Sci. 2022, 23, 4196 13 of 22

studies related to pain have been performed to this day [130,133,153]. Carvalho et al. [130]
performed an open-label, controlled, randomized study finding that placebos presented
in a positive context can be used in chronic lumbar pain. In the study, patients with at
least three months of chronic lumbar pain were randomly assigned to receive two tablets
of placebo taken twice a day or their usual treatment for three weeks, reporting a signifi-
cant decrease in their severity of pain score (95% interval confidence: 1.0–2.0). Likewise,
Kam-Hansen et al. [133] performed an open-label placebo study evaluating episodic mi-
graines, reporting superior efficiency in individuals treated with placebos compared to
those that did not receive any treatment.
The placebo effects of each treatment can be used to design therapeutic strategies that
improve the clinical results of the analgesic and limit its adverse effects [154]. In this context,
the placebo effect induces the release of endogenous opioids that facilitate the analgesic
action of exogenous opioids; therefore, it is possible to improve the response to analgesic
treatments by increasing the additional placebo effect [155]. Thus, through the development
of interventions that optimize the placebo effect towards the adaptation of the CNS for
pain relief, a potential progressive reduction in the administration of exogenous opioids is
possible [156]. There are various possibilities for taking advantage of placebo effects in the
context of pain, adapting the information on analgesic treatment, and associating its intake
with a positive context [155]. Based on the above, it is to be expected that the combination
of analgesic drugs and placebos would have better results in reducing pain than using each
strategy separately.
Recently, it has been described that the placebo effect in humans can generate an
increase in dopamine release in the dorsal and ventral striatum [74–76], reporting that
even 50% of patients with PD have shown response to placebo characterized by significant
motor manifestations [77,157–161]. Shetty et al. [162] reported that from 36 clinical assays
included in their study, 12 reported improvement after placebo treatment with PD, with
a variation in the improvement from 9% to 59%. Likewise, a double-blind study found
significant improvement in the group treated with pergolide and in the placebo group [163].
Alternatively, Goetz et al. [164] performed a randomized, multicenter, placebo-controlled
study in which they found that 14% of patients achieved motor function improvement
while they were on placebo. Another study performed by Goetz et al. [165] involved data
from 11 medical and surgical assays in patients with PD. They showed that the placebo
effect can be significant, especially with surgical intervention. Regarding motor symptoms,
bradykinesia is the one that has the greatest response to placebo [164,166], followed by
rigidity [164], gait, and tremor [164], respectively. There was a 94% improvement in
bradykinesia and 59% in gait [164]. Likewise, Bennedetti et al. [167] demonstrated that the
administration of placebo-induced clinical responses as large as the one from apomorphine
in rigidity.
The placebo effect has also been explored in other neurological disorders. Multiple
sclerosis has an unpredictable remission–relapse pattern, making it a challenge to sepa-
rate the placebo effect from the natural history of the disease in clinical assays. Despite
this, different neuroimaging studies have shown a decrease in the number of injuries
observed in magnetic resonance in the placebo groups [136,168,169]. In an assay per-
formed by Jacobs et al. [136] there was an improvement in the magnetic resonance of the
placebo group according to what was evaluated by the number of lesions potentiated by
gadolinium. In addition, a meta-analysis was performed by Beyenburg et al. [170], which
included 54 studies examining anticonvulsant drugs versus placebos in over 11,106 adults
and children with refractory epilepsy. They reported that there was a small difference
between anticonvulsant drugs and the placebo effect [170]. Similarly, a systematic review
that included 28 clinical assays evaluating multiple anticonvulsant drugs versus placebos
as refractory epilepsy treatment found a response in 18% of the patients receiving place-
bos [171]. These results are similar to what was reported by Guekht et al., who conducted a
meta-analysis that included 27 assays evaluating anticonvulsant drugs versus placebos in
adults with focal epilepsy, reporting response to placebos in 12.5% of the patients [172].
Int. J. Mol. Sci. 2022, 23, 4196 14 of 22

3.2. Psychiatric Disorders

Numerous studies have researched the placebo effect in the context of current psy-
chiatry, especially in depression. Although antidepressants offer a clear advantage over
placebos in patients with severe depression, the same is not true for those with mild de-
pression. These patients have shown a response rate to placebos close to 50%. Often, the
response rate between placebos and antidepressants cannot be differentiated [173]. Further-
more, no type of psychotherapy has consistently proven to be better than placebo [174]. It
has been hypothesized that common and possibly therapeutic characteristics of psychother-
apy, which include improvement expectation, support, and hope mobilization, are often
provided together with placebo. Different studies have estimated that the double-blind
response to placebo has 80% of the strength of double-blind antidepressant response in
patients with major depressive disorder in randomized controlled assays [132]. In this
sense, in an open-label, randomized placebo study, a positive difference was seen among
patients with major depressive disorder treated with open-label placebo and the control
group. However, the difference was not statistically significant [175].
The impact of the placebo effect on anxiety disorders has been explored. It has been
reported that the placebo effect in clinical assays involving this disorder ranges from 10%
to 60% [176–181]. Different randomized assays have shown that the placebo response
in anxiety disorders can be relevant and long-lasting. In this sense, improvement in the
placebo group in clinical trials has been stable and maintained after the use of the placebo
was suspended, while the patients using anxiolytic drugs suffered relapses [182,183]. On
the other hand, Faria et al. [137] performed a study in which it was shown that telling
patients who had been diagnosed with social anxiety disorder (SAD) that they were being
treated with an active drug doubled the efficacy and tripled the response rate.
Likewise, Sandler et al. [135] demonstrated that treatment with an open-label placebo
was acceptable and efficient in the short term in the case of some children with attention-
deficit and hyperactivity disorder (ADHD). In the study, the behavior of kids with ADHD
remained the same when the dose of the stimulus drug with the placebo was reduced, but it
deteriorated when the dose without the placebo was reduced. Alternatively, Weiss et al. [184]
examined the nature of the effect of placebo medication with medical treatment in alco-
hol dependency. It was found that the groups receiving a placebo along with medical
treatment were more likely to go to Alcoholic Anonymous meetings during the treatment
(32.7% and 32% vs. 20.4%) and were less likely to withdraw from treatment (14.1% and
22.9% 553 vs. 29.3%). However, more studies are needed in psychiatric settings to confirm
these findings.

3.3. Immunological Disorders

A great number of assays evaluating classical conditioning in different immune dis-
eases have been performed, showing its efficacy in animal models of Systemic Lupus
Erythematous (SLE) [185], rheumatoid arthritis [186], and asthma [187]. In a study involv-
ing rats with experimentally induced rheumatoid arthritis, re-exposure to a solution with
saccharine and vanilla flavor that had been previously combined with cyclophosphamide
resulted in a decrease in inflammatory processes [188]. Likewise, in a model in rodents with
SLE, mice with conditioned behavior showed relatively prolonged latency and survival
time when compared to the control group animals [189].
Numerous studies have highlighted the effects of placebo response in allergies, which
seems to be mediated by cognitive factors such as expectations. A decrease in symptoms
of type 1 allergic reactions in people treated with placebo with previous conditioning has
been reported [190]. Similarly, Goeber et al. [138] reported a placebo response in patients
with allergic rhinitis. These individuals were exposed to a conditioning protocol, receiving
desloratadine and a beverage for 5 days. Afterward, the patients were exposed to the
beverage and a placebo, showing improvement in the symptoms after this last exposure.
Different assays have also been able to show that placebo responses imitate the effects of a
drug to which the subjects have been previously exposed [190–192]. A randomized, open-
Int. J. Mol. Sci. 2022, 23, 4196 15 of 22

label placebo study evaluated two groups of 25 patients with allergic rhinitis comparing
the use of the open-label placebo with their usual treatment for two weeks. It was observed
that, at two weeks, there was a significant effect on the subjective experiences of 11 physical
symptoms with significant improvement in subjective well-being (p = 0.009). In addition,
a statistically significant reduction in symptoms was observed in the open-label placebo
group when compared with the group receiving their usual treatment [193].
Likewise, different studies have reported that placebo administration leads to an
improvement in objective parameters of lung function in asthma patients. These include
the forced expiratory volume in 1 s (FEV1), bronchial hyperactivity, and peak expiratory
flow (PEF) [187,188,194,195]. A second study found that the administration of placebowith
an inhaler was beneficial according to self-reported results, with an effect similar to that of
albuterol without the need for conditioning. However, no increase in FEV1 was observed
in asthmatic patients treated with placebo, unlike patients treated with albuterol [196].

4. Conclusions
There is sufficient evidence supporting the PNEI processes involved in the placebo ef-
fect and its possible therapeutic efficacy in different diseases. Classical conditioning stands
out among the psychologic mechanisms involved in the placebo effect. Neurobiological
effects have been found in the opioid, cannabinoid, and monoaminergic systems, as well
as possible immunomodulating responses and the secretion of hormones in both animal
models and humans. At the clinical level, the epicenter of research in the last decades has
been its use in pain management. However, recent studies have extended the research
to include neurological, immune, and psychiatric disorders. That said, more research is
needed to characterize the clinical usefulness of the placebo response in these scenarios,
without forgetting the ethical concerns involved in this therapeutic option that shows the
interaction of different body systems.

Author Contributions: Conceptualization: Á.O., J.S., N.G. and M.C.-C. Investigation: N.G., Á.O.,
D.A., J.S. and M.R.; Writing—original draft: N.G., Á.O., M.N. and D.A.; Writing—review & editing:
M.R., N.G., V.B., M.E.R.-G., O.M.-O., E.A.D.-C. and Á.O.; Funding acquisition: V.B., M.E.R.-G. and
E.A.D.-C. All authors have read and agreed to the published version of the manuscript.
Funding: This work was supported by research grant no. CC-0437-10-21-09-10 from Consejo de
Desarrollo Científico, Humanístico y Tecnológico (CONDES), University of Zulia, and research grant
no. FZ-0058-2007 from Fundacite-Zulia.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.

References
1. Jütte, R. The Early History of the Placebo. Complement. Ther. Med. 2013, 21, 94–97. [CrossRef] [PubMed]
2. Kerr, C.E.; Milne, I.; Kaptchuk, T.J. William Cullen and a Missing Mind-Body Link in the Early History of Placebos. J. R. Soc. Med.
2008, 101, 89–92. [CrossRef] [PubMed]
3. Tavel, M.E. The Placebo Effect: The Good, the Bad, and the Ugly. Am. J. Med. 2014, 127, 484–488. [CrossRef] [PubMed]
4. Colagiuri, B.; Schenk, L.A.; Kessler, M.D.; Dorsey, S.G.; Colloca, L. The Placebo Effect: From Concepts to Genes. Neuroscience 2015,
307, 171–190. [CrossRef]
5. Wager, T.D.; Atlas, L.Y. The Neuroscience of Placebo Effects: Connecting Context, Learning and Health. Nat. Rev. Neurosci. 2015,
16, 403–418. [CrossRef]
6. Klinger, R.; Colloca, L.; Bingel, U.; Flor, H. Placebo Analgesia: Clinical Applications. Pain 2014, 155, 1055–1058. [CrossRef]
7. Meyer, B.; Yuen, K.S.L.; Ertl, M.; Polomac, N.; Mulert, C.; Büchel, C.; Kalisch, R. Neural Mechanisms of Placebo Anxiolysis.
J. Neurosci. 2015, 35, 7365–7373. [CrossRef]
8. Frisaldi, E.; Carlino, E.; Zibetti, M.; Barbiani, D.; Dematteis, F.; Lanotte, M.; Lopiano, L.; Benedetti, F. The Placebo Effect on
Bradykinesia in Parkinson’s Disease with and without Prior Drug Conditioning. Mov. Disord. 2017, 32, 1474–1478. [CrossRef]
Int. J. Mol. Sci. 2022, 23, 4196 16 of 22

9. Tolusso, D.V.; Laurent, C.M.; Fullenkamp, A.M.; Tobar, D.A. Placebo Effect: Influence on Repeated Intermittent Sprint Performance
on Consecutive Days. J. Strength Cond. Res. 2015, 29, 1915–1924. [CrossRef]
10. Turi, Z.; Bjørkedal, E.; Gunkel, L.; Antal, A.; Paulus, W.; Mittner, M. Evidence for Cognitive Placebo and Nocebo Effects in Healthy
Individuals. Sci. Rep. 2018, 8, 17443. [CrossRef]
11. Benedetti, F. Placebo-Induced Improvements: How Therapeutic Rituals Affect the Patient’s Brain. J. Acupunct. Meridian Stud.
2012, 5, 97–103. [CrossRef]
12. Kong, J.; Spaeth, R.; Cook, A.; Kirsch, I.; Claggett, B.; Vangel, M.; Gollub, R.L.; Smoller, J.W.; Kaptchuk, T.J. Are All Placebo
Effects Equal? Placebo Pills, Sham Acupuncture, Cue Conditioning and Their Association. PLoS ONE 2013, 8, e67485. [CrossRef]
[PubMed]
13. Zheng, Y.-C.; Yuan, T.-T.; Liu, T. Is Acupuncture a Placebo Therapy? Complement. Ther. Med. 2014, 22, 724–730. [CrossRef]
14. Geuter, S.; Koban, L.; Wager, T.D. The Cognitive Neuroscience of Placebo Effects: Concepts, Predictions, and Physiology.
Annu. Rev. Neurosci. 2017, 40, 167–188. [CrossRef] [PubMed]
15. Eelen, P. Classical Conditioning: Classical Yet Modern. Psychol. Belg. 2018, 58, 196–211. [CrossRef]
16. Frisaldi, E.; Piedimonte, A.; Benedetti, F. Placebo and Nocebo Effects: A Complex Interplay Between Psychological Factors and
Neurochemical Networks. Am. J. Clin. Hypn. 2015, 57, 267–284. [CrossRef] [PubMed]
17. Colloca, L.; Miller, F.G. How Placebo Responses Are Formed: A Learning Perspective. Philos. Trans. R. Soc. B 2011, 366, 1859–1869.
[CrossRef]
18. Carlino, E.; Torta, D.M.E.; Piedimonte, A.; Frisaldi, E.; Vighetti, S.; Benedetti, F. Role of Explicit Verbal Information in Conditioned
Analgesia: Explicit Verbal Information in Conditioned Analgesia. Eur. J. Pain 2015, 19, 546–553. [CrossRef] [PubMed]
19. Ursano, A.M.; Sonnenberg, S.M.; Ursano, R.J. Physician-Patient Relationship. In Psychiatry; Tasman, A., Kay, J., Lieberman, J.A.,
First, M.B., Riba, M.B., Eds.; John Wiley & Sons, Ltd.: Chichester, UK, 2015; pp. 20–33. ISBN 978-1-118-75337-8.
20. Rabinovich, M.; Kacen, L. Transference in View of a Classical Conditioning Model. Am. J. Psychol. 2012, 125, 209–223. [CrossRef]
21. Carlino, E.; Benedetti, F. Placebo and Nocebo Effects. In The Handbook of Behavioral Medicine; Mostofsky, D.I., Ed.; John
Wiley & Sons, Ltd.: Oxford, UK, 2014; pp. 36–57. ISBN 978-1-118-45394-0.
22. Brown, W.A. Expectation, the Placebo Effect and the Response to Treatment. R. I. Med. J. 2015, 98, 19–21.
23. Price, D.D.; Finniss, D.G.; Benedetti, F. A Comprehensive Review of the Placebo Effect: Recent Advances and Current Thought.
Annu. Rev. Psychol. 2008, 59, 565–590. [CrossRef] [PubMed]
24. Campbell, J.N.; Meyer, R.A. Mechanisms of Neuropathic Pain. Neuron 2006, 52, 77–92. [CrossRef] [PubMed]
25. Vachon-Presseau, E.; Berger, S.E.; Abdullah, T.B.; Huang, L.; Cecchi, G.; Griffith, J.W.; Schnitzer, T.J.; Apkarian, A.V. Brain and
Psychological Determinants of Placebo Pill Response in Chronic Pain Patients. Neuroscience 2017, 9, 3397. [CrossRef] [PubMed]
26. Wanigasekera, V.; Wartolowska, K.; Huggins, J.P.; Duff, E.P.; Vennart, W.; Whitlock, M.; Massat, N.; Pauer, L.; Rogers, P.;
Hoggart, B.; et al. Disambiguating Pharmacological Mechanisms from Placebo in Neuropathic Pain Using Functional Neuroimaging.
Br. J. Anaesth. 2018, 120, 299–307. [CrossRef]
27. Wager, T.D.; Atlas, L.Y.; Leotti, L.A.; Rilling, J.K. Predicting Individual Differences in Placebo Analgesia: Contributions of Brain
Activity during Anticipation and Pain Experience. J. Neurosci. 2011, 31, 439–452. [CrossRef]
28. Xu, L.; Wan, Y.; Ma, L.; Zheng, J.; Han, B.; Liu, F.-Y.; Yi, M.; Wan, Y. A Context-Based Analgesia Model in Rats: Involvement of
Prefrontal Cortex. Neurosci. Bull. 2018, 34, 1047–1057. [CrossRef]
29. Hikida, T.; Morita, M.; Macpherson, T. Neural Mechanisms of the Nucleus Accumbens Circuit in Reward and Aversive Learning.
Neurosci. Res. 2016, 108, 1–5. [CrossRef]
30. Watanabe, M. Emotional and Motivational Functions of the Prefrontal Cortex. Brain Nerve 2016, 68, 1291–1299. [CrossRef]
31. Krummenacher, P.; Candia, V.; Folkers, G.; Schedlowski, M.; Schönbächler, G. Prefrontal Cortex Modulates Placebo Analgesia.
Pain 2010, 148, 368–374. [CrossRef]
32. Peciña, M.; Bohnert, A.S.B.; Sikora, M.; Avery, E.T.; Langenecker, S.A.; Mickey, B.J.; Zubieta, J.-K. Association between
Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.
JAMA Psychiatry 2015, 72, 1087–1094. [CrossRef]
33. Petrovic, P.; Dietrich, T.; Fransson, P.; Andersson, J.; Carlsson, K.; Ingvar, M. Placebo in Emotional Processing—Induced
Expectations of Anxiety Relief Activate a Generalized Modulatory Network. Neuron 2005, 46, 957–969. [CrossRef] [PubMed]
34. Duarte, D.F. Uma Breve História Do Ópio e Dos Opióides. Rev. Bras. Anestesiol. 2005, 55, 135–146. [CrossRef] [PubMed]
35. Rosenblum, A.; Marsch, L.A.; Joseph, H.; Portenoy, R.K. Opioids and the Treatment of Chronic Pain: Controversies, Current
Status, and Future Directions. Exp. Clin. Psychopharmacol. 2008, 16, 405–416. [CrossRef] [PubMed]
36. Hughes, J.; Smith, T.W.; Kosterlitz, H.W.; Fothergill, L.A.; Morgan, B.A.; Morris, H.R. Identification of Two Related Pentapeptides
from the Brain with Potent Opiate Agonist Activity. Nature 1975, 258, 577–580. [CrossRef] [PubMed]
37. Grossman, A.; Clement-Jones, V. Opiate Receptors: Enkephalins and Endorphins. Clin. Endocrinol. Metab. 1983, 12, 31–56.
[CrossRef]
38. Gu, Z.-H.; Wang, B.; Kou, Z.-Z.; Bai, Y.; Chen, T.; Dong, Y.-L.; Li, H.; Li, Y.-Q. Endomorphins: Promising Endogenous Opioid
Peptides for the Development of Novel Analgesics. Neurosignals 2017, 25, 98–116. [CrossRef]
39. Schwarzer, C. 30 Years of Dynorphins—New Insights on Their Functions in Neuropsychiatric Diseases. Pharmacol. Ther. 2009,
123, 353–370. [CrossRef]
Int. J. Mol. Sci. 2022, 23, 4196 17 of 22

40. Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S.
Crystal Structure of the M-Opioid Receptor Bound to a Morphinan Antagonist. Nature 2012, 485, 321–326. [CrossRef]
41. Granier, S.; Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Weis, W.I.; Kobilka, B.K. Structure of the δ-Opioid Receptor Bound
to Naltrindole. Nature 2012, 485, 400–404. [CrossRef]
42. Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G.W.; Vardy, E.; Liu, W.; Thompson, A.A.; Huang, X.-P.; Carroll, F.I.; et al.
Structure of the Human κ-Opioid Receptor in Complex with JDTic. Nature 2012, 485, 327–332. [CrossRef]
43. Peng, J.; Sarkar, S.; Chang, S.L. Opioid Receptor Expression in Human Brain and Peripheral Tissues Using Absolute Quantitative
Real-Time RT-PCR. Drug Alcohol Depend. 2012, 124, 223–228. [CrossRef] [PubMed]
44. Pathan, H.; Williams, J. Basic Opioid Pharmacology: An Update. Br. J. Pain 2012, 6, 11–16. [CrossRef] [PubMed]
45. Stein, C. Opioid Receptors. Annu. Rev. Med. 2016, 67, 433–451. [CrossRef] [PubMed]
46. Levine, J.D.; Gordon, N.C.; Fields, H.L. The Mechanism of Placebo Analgesia. Lancet 1978, 2, 654–657. [CrossRef]
47. Eippert, F.; Bingel, U.; Schoell, E.D.; Yacubian, J.; Klinger, R.; Lorenz, J.; Büchel, C. Activation of the Opioidergic Descending Pain
Control System Underlies Placebo Analgesia. Neuron 2009, 63, 533–543. [CrossRef]
48. Lipman, J.J.; Miller, B.E.; Mays, K.S.; Miller, M.N.; North, W.C.; Byrne, W.L. Peak B Endorphin Concentration in Cerebrospinal
Fluid: Reduced in Chronic Pain Patients and Increased during the Placebo Response. Psychopharmacology 1990, 102, 112–116.
[CrossRef] [PubMed]
49. Zhang, R.-R.; Zhang, W.-C.; Wang, J.-Y.; Guo, J.-Y. The Opioid Placebo Analgesia Is Mediated Exclusively through µ-Opioid
Receptor in Rat. Int. J. Neuropsychopharmacol. 2013, 16, 849–856. [CrossRef] [PubMed]
50. Peciña, M.; Love, T.; Stohler, C.S.; Goldman, D.; Zubieta, J.-K. Effects of the Mu Opioid Receptor Polymorphism (OPRM1 A118G)
on Pain Regulation, Placebo Effects and Associated Personality Trait Measures. Neuropsychopharmacology 2015, 40, 957–965.
[CrossRef] [PubMed]
51. Zubieta, J.-K. Placebo Effects Mediated by Endogenous Opioid Activity on-Opioid Receptors. J. Neurosci. 2005, 25, 7754–7762.
[CrossRef]
52. Scott, D.J.; Stohler, C.S.; Egnatuk, C.M.; Wang, H.; Koeppe, R.A.; Zubieta, J.-K. Placebo and Nocebo Effects Are Defined by
Opposite Opioid and Dopaminergic Responses. Arch. Gen. Psychiatry 2008, 65, 220. [CrossRef]
53. Zubieta, J.-K.; Stohler, C.S. Neurobiological Mechanisms of Placebo Responses. Ann. N. Y. Acad. Sci. 2009, 1156, 198–210.
[CrossRef]
54. Atlas, L.Y.; Wager, T.D. A Meta-Analysis of Brain Mechanisms of Placebo Analgesia: Consistent Findings and Unanswered
Questions. In Placebo Handbook of Experimental Pharmacology; Benedetti, F., Enck, P., Frisaldi, E., Schedlowski, M., Eds.; Springer:
Berlin/Heidelberg, Germany, 2014; Volume 225, pp. 37–69. ISBN 978-3-662-44518-1.
55. Eippert, F.; Finsterbusch, J.; Bingel, U.; Büchel, C. Direct Evidence for Spinal Cord Involvement in Placebo Analgesia. Science 2009,
326, 404. [CrossRef]
56. Amanzio, M.; Benedetti, F. Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus
Conditioning-Activated Specific Subsystems. J. Neurosci. 1999, 19, 484–494. [CrossRef] [PubMed]
57. Vase, L.; Robinson, M.E.; Verne, N.G.; Price, D.D. Increased Placebo Analgesia over Time in Irritable Bowel Syndrome (IBS)
Patients Is Associated with Desire and Expectation but Not Endogenous Opioid Mechanisms. Pain 2005, 115, 338–347. [CrossRef]
[PubMed]
58. Guo, J.-Y.; Wang, J.-Y.; Luo, F. Dissection of Placebo Analgesia in Mice: The Conditions for Activation of Opioid and Non-Opioid
Systems. J. Psychopharmacol. 2010, 24, 1561–1567. [CrossRef] [PubMed]
59. Lee, I.-S.; Lee, B.; Park, H.-J.; Olausson, H.; Enck, P.; Chae, Y. A New Animal Model of Placebo Analgesia: Involvement of the
Dopaminergic System in Reward Learning. Sci. Rep. 2015, 5, 17140. [CrossRef] [PubMed]
60. Mackie, K. Distribution of Cannabinoid Receptors in the Central and Peripheral Nervous System. Handb. Exp. Pharmacol. 2005,
168, 299–325. [CrossRef]
61. Dhopeshwarkar, A.; Mackie, K. Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold? Mol. Pharmacol.
2014, 86, 430–437. [CrossRef] [PubMed]
62. Woodhams, S.G.; Chapman, V.; Finn, D.P.; Hohmann, A.G.; Neugebauer, V. The Cannabinoid System and Pain. Neuropharmacology
2017, 124, 105–120. [CrossRef] [PubMed]
63. Benedetti, F.; Amanzio, M.; Rosato, R.; Blanchard, C. Nonopioid Placebo Analgesia Is Mediated by CB1 Cannabinoid Receptors.
Nat. Med. 2011, 17, 1228–1230. [CrossRef]
64. Peciña, M.; Martínez-Jauand, M.; Hodgkinson, C.; Stohler, C.S.; Goldman, D.; Zubieta, J.K. FAAH Selectively Influences Placebo
Effects. Mol. Psychiatry 2014, 19, 385–391. [CrossRef] [PubMed]
65. Brodermann, H.M. Pain, Pleasure and Placebo: The Cannabinoids in Reward Processing and the Perception of Pain. Ment. Health
Addict. Res. 2016, 1, 59–63. [CrossRef]
66. Klein, M.O.; Battagello, D.S.; Cardoso, A.R.; Hauser, D.N.; Bittencourt, J.C.; Correa, R.G. Dopamine: Functions, Signaling, and
Association with Neurological Diseases. Cell Mol. Neurobiol. 2019, 39, 31–59. [CrossRef]
67. Beaulieu, J.-M.; Gainetdinov, R.R. The Physiology, Signaling, and Pharmacology of Dopamine Receptors. Pharmacol. Rev. 2011,
63, 182–217. [CrossRef]
68. Beaulieu, J.-M.; Espinoza, S.; Gainetdinov, R.R. Dopamine Receptors—IUPHAR Review 13: Dopamine Receptors. Br. J. Pharmacol.
2015, 172, 1–23. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2022, 23, 4196 18 of 22

69. Irizarry, K.J.L.; Licinio, J. An Explanation for the Placebo Effect? Science 2005, 307, 1411–1412. [CrossRef] [PubMed]
70. Peciña, M.; Zubieta, J.-K. Molecular Mechanisms of Placebo Responses in Humans. Mol. Psychiatry 2015, 20, 416–423. [CrossRef]
[PubMed]
71. Jarcho, J.M.; Feier, N.A.; Labus, J.S.; Naliboff, B.; Smith, S.R.; Hong, J.-Y.; Colloca, L.; Tillisch, K.; Mandelkern, M.A.;
Mayer, E.A.; et al. Placebo Analgesia: Self-Report Measures and Preliminary Evidence of Cortical Dopamine Release Associated
with Placebo Response. NeuroImage Clin. 2016, 10, 107–114. [CrossRef] [PubMed]
72. Kaasinen, V.; Aalto, S.; Nagren, K.; Rinne, J.O. Expectation of Caffeine Induces Dopaminergic Responses in Humans. Eur. J.
Neurosci. 2004, 19, 2352–2356. [CrossRef] [PubMed]
73. Schulz-Schaeffer, W. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson’s Disease? Biomolecules
2015, 5, 1467–1479. [CrossRef] [PubMed]
74. De la Fuente-Fernández, R.; Ruth, T.J.; Sossi, V.; Schulzer, M.; Calne, D.B.; Stoessl, A.J. Expectation and Dopamine Release:
Mechanism of the Placebo Effect in Parkinson’s Disease. Science 2001, 293, 1164–1166. [CrossRef] [PubMed]
75. De la Fuente-Fernández, R.; Phillips, A.G.; Zamburlini, M.; Sossi, V.; Calne, D.B.; Ruth, T.J.; Stoessl, A.J. Dopamine Release in
Human Ventral Striatum and Expectation of Reward. Behav. Brain Res. 2002, 136, 359–363. [CrossRef]
76. Strafella, A.P.; Ko, J.H.; Monchi, O. Therapeutic Application of Transcranial Magnetic Stimulation in Parkinson’s Disease:
The Contribution of Expectation. NeuroImage 2006, 31, 1666–1672. [CrossRef] [PubMed]
77. Lidstone, S.C.; Schulzer, M.; Dinelle, K.; Mak, E.; Sossi, V.; Ruth, T.J.; de la Fuente-Fernández, R.; Phillips, A.G.; Stoessl, A.J.
Effects of Expectation on Placebo-Induced Dopamine Release in Parkinson Disease. Arch. Gen. Psychiatry 2010, 67, 857. [CrossRef]
78. Quattrone, A.; Barbagallo, G.; Cerasa, A.; Stoessl, A.J. Neurobiology of Placebo Effect in Parkinson’s Disease: What We Have
Learned and Where We Are Going: Placebo Effect in PD. Mov. Disord. 2018, 33, 1213–1227. [CrossRef] [PubMed]
79. Haour, F. Mechanisms of the Placebo Effect and of Conditioning. Neuroimmunomodulation 2005, 12, 195–200. [CrossRef]
80. Vinar, O. Addiction to Placebo. Am. J. Psychiatry 1978, 135, 1000. [CrossRef]
81. Kessner, S.; Sprenger, C.; Wrobel, N.; Wiech, K.; Bingel, U. Effect of Oxytocin on Placebo Analgesia: A Randomized Study. JAMA
2013, 310, 1733–1735. [CrossRef] [PubMed]
82. Skvortsova, A.; Veldhuijzen, D.S.; Van Middendorp, H.; Van den Bergh, O.; Evers, A.W.M. Enhancing Placebo Effects in Somatic
Symptoms Through Oxytocin. Psychosom. Med. 2018, 80, 353–360. [CrossRef] [PubMed]
83. Colloca, L.; Pine, D.S.; Ernst, M.; Miller, F.G.; Grillon, C. Vasopressin Boosts Placebo Analgesic Effects in Women: A Randomized
Trial. Biol. Psychiatry 2016, 79, 794–802. [CrossRef] [PubMed]
84. Boggero, I.A.; Segerstrom, S.C. Human Psychoneuroimmunology. In Encyclopedia of Mental Health; Elsevier: Amsterdam,
The Netherlands, 2016; pp. 343–349. ISBN 978-0-12-397753-3.
85. Dhabhar, F.S.; Malarkey, W.B.; Neri, E.; McEwen, B.S. Stress-Induced Redistribution of Immune Cells—From Barracks to
Boulevards to Battlefields: A Tale of Three Hormones—Curt Richter Award Winner. Psychoneuroendocrinology 2012, 37, 1345–1368.
[CrossRef] [PubMed]
86. Rohleder, N. Acute and Chronic Stress Induced Changes in Sensitivity of Peripheral Inflammatory Pathways to the Signals of
Multiple Stress Systems—2011 Curt Richter Award Winner. Psychoneuroendocrinology 2012, 37, 307–316. [CrossRef] [PubMed]
87. Morey, J.N.; Boggero, I.A.; Scott, A.B.; Segerstrom, S.C. Current Directions in Stress and Human Immune Function. Curr. Opin.
Psychol. 2015, 5, 13–17. [CrossRef] [PubMed]
88. Herkenham, M.; Kigar, S.L. Contributions of the Adaptive Immune System to Mood Regulation: Mechanisms and Pathways of
Neuroimmune Interactions. Prog. Neuropsychopharmacol. Biol. Psychiatry 2017, 79, 49–57. [CrossRef]
89. Bonaz, B.; Sinniger, V.; Pellissier, S. Anti-Inflammatory Properties of the Vagus Nerve: Potential Therapeutic Implications of
Vagus Nerve Stimulation: Anti-Inflammatory Effect of Vagus Nerve Stimulation. J. Physiol. 2016, 594, 5781–5790. [CrossRef]
90. Madden, K.S. Sympathetic Neural-Immune Interactions Regulate Hematopoiesis, Thermoregulation and Inflammation in
Mammals. Dev. Comp. Immunol. 2017, 66, 92–97. [CrossRef]
91. Bonaz, B.; Sinniger, V.; Pellissier, S. The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastroin-
testinal Tract. Front. Immunol. 2017, 8, 1452. [CrossRef]
92. Erickson, M.A.; Banks, W.A. Neuroimmune Axes of the Blood–Brain Barriers and Blood–Brain Interfaces: Bases for Physiological
Regulation, Disease States, and Pharmacological Interventions. Pharmacol. Rev. 2018, 70, 278–314. [CrossRef]
93. Quan, N. In-Depth Conversation: Spectrum and Kinetics of Neuroimmune Afferent Pathways. Brain Behav. Immun. 2014, 40, 1–8.
[CrossRef]
94. Prossin, A.; Koch, A.; Campbell, P.; Laumet, G.; Stohler, C.S.; Dantzer, R.; Zubieta, J.-K. Effects of Placebo Administration on
Immune Mechanisms and Relationships with Central Endogenous Opioid Neurotransmission. Mol. Psychiatry 2021, in press.
[CrossRef]
95. Albring, A.; Wendt, L.; Benson, S.; Witzke, O.; Kribben, A.; Engler, H.; Schedlowski, M. Placebo Effects on the Immune Response
in Humans: The Role of Learning and Expectation. PLoS ONE 2012, 7, e49477. [CrossRef]
96. Hadamitzky, M.; Sondermann, W.; Benson, S.; Schedlowski, M. Placebo Effects in the Immune System. In International Review of
Neurobiology; Elsevier: Amsterdam, The Netherlands, 2018; Volume 138, pp. 39–59. ISBN 978-0-12-814325-4.
97. Exton, M.S.; von Hörsten, S.; Schult, M.; Vöge, J.; Strubel, T.; Donath, S.; Steinmüller, C.; Seeliger, H.; Nagel, E.;
Westermann, J.; et al. Behaviorally Conditioned Immunosuppression Using Cyclosporine A: Central Nervous System
Reduces IL-2 Production via Splenic Innervation. J. Neuroimmunol. 1998, 88, 182–191. [CrossRef]
Int. J. Mol. Sci. 2022, 23, 4196 19 of 22

98. Exton, M.S.; Schult, M.; Donath, S.; Strubel, T.; Bode, U.; del Rey, A.; Westermann, J.; Schedlowski, M. Conditioned Immunosup-
pression Makes Subtherapeutic Cyclosporin Effective via Splenic Innervation. Am. J. Physiol. 1999, 276, R1710–R1717. [CrossRef]
[PubMed]
99. Xie, Y.; Frede, S.; Harnish, M.J.; Exton, M.S.; Schedlowski, M. Beta-Adrenoceptor-Induced Inhibition of Rat Splenocyte Prolifera-
tion: Cytokine Gene Transcription as the Target of Action. Immunobiology 2002, 206, 345–353. [CrossRef]
100. Exton, M.S.; Gierse, C.; Meier, B.; Mosen, M.; Xie, Y.; Frede, S.; Goebel, M.U.; Limmroth, V.; Schedlowski, M. Behaviorally
Conditioned Immunosuppression in the Rat Is Regulated via Noradrenaline and Beta-Adrenoceptors. J. Neuroimmunol. 2002,
131, 21–30. [CrossRef]
101. Pacheco-López, G.; Doenlen, R.; Krügel, U.; Arnold, M.; Wirth, T.; Riether, C.; Engler, A.; Niemi, M.-B.; Christians, U.;
Engler, H.; et al. Neurobehavioural Activation during Peripheral Immunosuppression. Int. J. Neuropsychopharmacol. 2013,
16, 137–149. [CrossRef]
102. Hörbelt, T.; Hetze, S.; Schedlowski, M.; Lückemann, L. Die gelernte Placeboantwort im Immunsystem. Nervenarzt 2020,
91, 667–674. [CrossRef]
103. Wirth, T.; Ober, K.; Prager, G.; Vogelsang, M.; Benson, S.; Witzke, O.; Kribben, A.; Engler, H.; Schedlowski, M. Repeated Recall of
Learned Immunosuppression: Evidence from Rats and Men. Brain Behav. Immun. 2011, 25, 1444–1451. [CrossRef]
104. Kirchhof, J.; Petrakova, L.; Brinkhoff, A.; Benson, S.; Schmidt, J.; Unteroberdörster, M.; Wilde, B.; Kaptchuk, T.J.; Witzke, O.;
Schedlowski, M. Learned Immunosuppressive Placebo Responses in Renal Transplant Patients. Proc. Natl. Acad. Sci. USA 2018,
115, 4223–4227. [CrossRef]
105. Lueckemann, L.; Bösche, K.; Engler, H.; Schwitalla, J.-C.; Hadamitzky, M.; Schedlowski, M. Pre-Exposure to the Unconditioned or
Conditioned Stimulus Does Not Affect Learned Immunosuppression in Rats. Brain Behav. Immun. 2016, 51, 252–257. [CrossRef]
106. Buske-Kirschbaum, A.; Kirschbaum, C.; Stierle, H.; Lehnert, H.; Hellhammer, D. Conditioned Increase of Natural Killer Cell
Activity (NKCA) in Humans. Psychosom. Med. 1992, 54, 123–132. [CrossRef] [PubMed]
107. Buske-Kirschbaum, A.; Kirschbaum, C.; Stierle, H.; Jabaij, L.; Hellhammer, D. Conditioned Manipulation of Natural Killer (NK)
Cells in Humans Using a Discriminative Learning Protocol. Biol. Psychol. 1994, 38, 143–155. [CrossRef]
108. Grigoleit, J.-S.; Kullmann, J.S.; Winkelhaus, A.; Engler, H.; Wegner, A.; Hammes, F.; Oberbeck, R.; Schedlowski, M. Single-
Trial Conditioning in a Human Taste-Endotoxin Paradigm Induces Conditioned Odor Aversion but Not Cytokine Responses.
Brain Behav. Immun. 2012, 26, 234–238. [CrossRef] [PubMed]
109. Coover, G.D.; Sutton, B.R.; Heybach, J.P. Conditioning Decreases in Plasma Corticosterone Level in Rats by Paring Stimuli with
Daily Feedings. J. Comp. Physiol. Psychol. 1977, 91, 716–726. [CrossRef] [PubMed]
110. Benedetti, F.; Pollo, A.; Lopiano, L.; Lanotte, M.; Vighetti, S.; Rainero, I. Conscious Expectation and Unconscious Conditioning in
Analgesic, Motor, and Hormonal Placebo/Nocebo Responses. J. Neurosci. 2003, 23, 4315–4323. [CrossRef] [PubMed]
111. Barreto, R.E.; Volpato, G.L. Evaluating Feeding as Unconditioned Stimulus for Conditioning of an Endocrine Effect in Nile Tilapia.
Physiol. Behav. 2007, 92, 867–872. [CrossRef] [PubMed]
112. Ader, R. Conditioned Adrenocortical Steroid Elevations in the Rat. J. Comp. Physiol. Psychol. 1976, 90, 1156–1163. [CrossRef]
113. Hall, G.; Stockhorst, U.; Enck, P.; Klosterhalfen, S. Overshadowing and Latent Inhibition in Nausea-Based Context Conditioning
in Humans: Theoretical and Practical Implications. Q. J. Exp. Psychol. 2016, 69, 1227–1238. [CrossRef]
114. Sabbioni, M.E.; Bovbjerg, D.H.; Mathew, S.; Sikes, C.; Lasley, B.; Stokes, P.E. Classically Conditioned Changes in Plasma Cortisol
Levels Induced by Dexamethasone in Healthy Men. FASEB J. 1997, 11, 1291–1296. [CrossRef]
115. Davis, K.W.; Cepeda-Benito, A.; Harraid, J.H.; Wellman, P.J. Plasma Corticosterone in the Rat in Response to Nicotine and Saline
Injections in a Context Previously Paired or Unpaired with Nicotine. Psychopharmacology 2005, 180, 466–472. [CrossRef]
116. Stockhorst, U.; Gritzmann, E.; Klopp, K.; Schottenfeld-Naor, Y.; Hubinger, A.; Berresheim, H.-W.; Steingruber, H.-J.; Gries, F.A.
Classical Conditioning of Insulin Effects in Healthy Humans. Psychosom. Med. 1999, 61, 424–435. [CrossRef] [PubMed]
117. Detke, M.J.; Brandon, S.E.; Weingarten, H.P.; Rodin, J.; Wagner, A.R. Modulation of Behavioral and Insulin Responses by
Contextual Stimuli Paired with Food. Physiol. Behav. 1989, 45, 845–851. [CrossRef]
118. Roozendaal, B.; Oldenburger, W.P.; Strubbe, J.H.; Koolhaas, J.M.; Bohus, B. The Central Amygdala Is Involved in the Conditioned
but Not in the Meal-Induced Cephalic Insulin Response in the Rat. Neurosci. Lett. 1990, 116, 210–215. [CrossRef]
119. Stockhorst, U.; Mahl, N.; Krueger, M.; Huenig, A.; Schottenfeld-Naor, Y.; Huebinger, A.; Berresheim, H.-W.; Steingrueber, H.-J.;
Scherbaum, W.A. Classical Conditioning and Conditionability of Insulin and Glucose Effects in Healthy Humans. Physiol. Behav.
2004, 81, 375–388. [CrossRef]
120. Stockhorst, U.; de Fries, D.; Steingrueber, H.-J.; Scherbaum, W.A. Unconditioned and Conditioned Effects of Intranasally
Administered Insulin vs. Placebo in Healthy Men: A Randomised Controlled Trial. Diabetologia 2011, 54, 1502–1506. [CrossRef]
121. Overduin, J.; Jansen, A. Conditioned Insulin and Blood Sugar Responses in Humans in Relation to Binge Eating. Physiol. Behav.
1997, 61, 569–575. [CrossRef]
122. Onaka, T.; Yagi, K. Oxytocin Release from the Neurohypophysis after the Taste Stimuli Previously Paired with Intravenous
Cholecystokinin in Anaesthetized Rats. J. Neuroendocrinol. 1998, 10, 309–316. [CrossRef]
123. Tancin, V.; Kraetzl, W.-D.; Schams, D.; Bruckmaier, R.M. The Effects of Conditioning to Suckling, Milking and of Calf Presence on
the Release of Oxytocin in Dairy Cows. Appl. Anim. Behav. Sci. 2001, 72, 235–246. [CrossRef]
124. Graham, J.M.; Desjardins, C. Classical Conditioning: Induction of Luteinizing Hormone and Testosterone Secretion in Anticipation
of Sexual Activity. Science 1980, 210, 1039–1041. [CrossRef]
Int. J. Mol. Sci. 2022, 23, 4196 20 of 22

125. Golombek, D.A.; Chuluyan, H.E.; Kanterewicz, B.I.; Cardinali, D.P. Increased Pineal Melatonin Content Coupled to Restricted
Water Availability in a Pavlovian Conditioning Paradigm in Rats. J. Neural Transm. 1994, 98, 237–246. [CrossRef]
126. Keller, A.; Akintola, T.; Colloca, L. Placebo Analgesia in Rodents: Current and Future Research. Int. Rev. Neurobiol. 2018, 138, 1–15.
[CrossRef] [PubMed]
127. Annoni, M.; Miller, F.G. Placebos in Clinical Practice: An Ethical Overview. Douleur Analg. 2014, 27, 215–220. [CrossRef]
128. American Medical Association. American Medical Association Code of Ethics Opinion 8.083 (2006) Placebo Use in Clinical Practice;
American Medical Association: Chicago, IL, USA, 2006.
129. Charlesworth, J.E.G.; Petkovic, G.; Kelley, J.M.; Hunter, M.; Onakpoya, I.; Roberts, N.; Miller, F.G.; Howick, J. Effects of Placebos
without Deception Compared with No Treatment: A Systematic Review and Meta-Analysis. J. Evid. Based Med. 2017, 10, 97–107.
[CrossRef] [PubMed]
130. Carvalho, C.; Caetano, J.M.; Cunha, L.; Rebouta, P.; Kaptchuk, T.J.; Kirsch, I. Open-Label Placebo Treatment in Chronic Low Back
Pain: A Randomized Controlled Trial. Pain 2016, 157, 2766–2772. [CrossRef]
131. Kaptchuk, T.J.; Friedlander, E.; Kelley, J.M.; Sanchez, M.N.; Kokkotou, E.; Singer, J.P.; Kowalczykowski, M.; Miller, F.G.; Kirsch, I.;
Lembo, A.J. Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome. PLoS ONE 2010, 5, e15591.
[CrossRef] [PubMed]
132. Kelley, J.M.; Kaptchuk, T.J.; Cusin, C.; Lipkin, S.; Fava, M. Open-Label Placebo for Major Depressive Disorder: A Pilot Randomized
Controlled Trial. Psychother. Psychosom. 2012, 81, 312–314. [CrossRef]
133. Kam-Hansen, S.; Jakubowski, M.; Kelley, J.M.; Kirsch, I.; Hoaglin, D.C.; Kaptchuk, T.J.; Burstein, R. Altered Placebo and Drug
Labeling Changes the Outcome of Episodic Migraine Attacks. Sci. Transl. Med. 2014, 6, 218ra5. [CrossRef]
134. Krueger, G.G.; Elewski, B.; Papp, K.; Wang, A.; Zitnik, R.; Jahreis, A. Patients with Psoriasis Respond to Continuous Open-Label
Etanercept Treatment after Initial Incomplete Response in a Randomized, Placebo-Controlled Trial. J. Am. Acad. Dermatol. 2006,
54, S112–S119. [CrossRef]
135. Sandler, A.D.; Bodfish, J.W. Open-Label Use of Placebos in the Treatment of ADHD: A Pilot Study. Child Care Health Dev. 2008,
34, 104–110. [CrossRef] [PubMed]
136. Jacobs, L.D.; Cookfair, D.L.; Rudick, R.A.; Herndon, R.M.; Richert, J.R.; Salazar, A.M.; Fischer, J.S.; Goodkin, D.E.; Granger, C.V.;
Simon, J.H.; et al. Intramuscular Interferon Beta-1a for Disease Progression in Relapsing Multiple Sclerosis. The Multiple Sclerosis
Collaborative Research Group (MSCRG). Ann. Neurol. 1996, 39, 285–294. [CrossRef]
137. Faria, V.; Gingnell, M.; Hoppe, J.M.; Hjorth, O.; Alaie, I.; Frick, A.; Hultberg, S.; Wahlstedt, K.; Engman, J.; Månsson, K.N.T.; et al.
Do You Believe It? Verbal Suggestions Influence the Clinical and Neural Effects of Escitalopram in Social Anxiety Disorder:
A Randomized Trial. EBio Med. 2017, 24, 179–188. [CrossRef] [PubMed]
138. Goebel, M.U.; Meykadeh, N.; Kou, W.; Schedlowski, M.; Hengge, U.R. Behavioral Conditioning of Antihistamine Effects in
Patients with Allergic Rhinitis. Psychother. Psychosom. 2008, 77, 227–234. [CrossRef] [PubMed]
139. Bardo, M.T.; Valone, J.M. Morphine-Conditioned Analgesia Using a Taste Cue: Dissociation of Taste Aversion and Analgesia.
Psychopharmacology 1994, 114, 269–274. [CrossRef]
140. Miller, J.S.; Kelly, K.S.; Neisewander, J.L.; McCoy, D.F.; Bardo, M.T. Conditioning of Morphine-Induced Taste Aversion and
Analgesia. Psychopharmacology 1990, 101, 472–480. [CrossRef] [PubMed]
141. Valone, J.M.; Randall, C.K.; Kraemer, P.J.; Bardo, M.T. Olfactory Cues and Morphine-Induced Conditioned Analgesia in Rats.
Pharmacol. Biochem. Behav. 1998, 60, 115–118. [CrossRef]
142. Akintola, T.; Tricou, C.; Raver, C.; Castro, A.; Colloca, L.; Keller, A. In Search of a Rodent Model of Placebo Analgesia in Chronic
Orofacial Neuropathic Pain. Neurobiol. Pain 2019, 6, 100033. [CrossRef] [PubMed]
143. McNabb, C.T.; White, M.M.; Harris, A.L.; Fuchs, P.N. The Elusive Rat Model of Conditioned Placebo Analgesia. Pain 2014,
155, 2022–2032. [CrossRef] [PubMed]
144. Zeng, Y.; Hu, D.; Yang, W.; Hayashinaka, E.; Wada, Y.; Watanabe, Y.; Zeng, Q.; Cui, Y. A Voxel-Based Analysis of Neurobiological
Mechanisms in Placebo Analgesia in Rats. Neuroimage 2018, 178, 602–612. [CrossRef] [PubMed]
145. Mbizvo, G.K.; Nolan, S.J.; Nurmikko, T.J.; Goebel, A. Placebo Responses in Long-Standing Complex Regional Pain Syndrome:
A Systematic Review and Meta-Analysis. J. Pain 2015, 16, 99–115. [CrossRef] [PubMed]
146. Loder, E.; Goldstein, R.; Biondi, D. Placebo Effects in Oral Triptan Trials: The Scientific and Ethical Rationale for Continued Use of
Placebo Controls. Cephalalgia 2005, 25, 124–131. [CrossRef] [PubMed]
147. Meissner, K.; Fässler, M.; Rücker, G.; Kleijnen, J.; Hróbjartsson, A.; Schneider, A.; Antes, G.; Linde, K. Differential Effectiveness
of Placebo Treatments: A Systematic Review of Migraine Prophylaxis. JAMA Intern. Med. 2013, 173, 1941–1951. [CrossRef]
[PubMed]
148. Cragg, J.J.; Warner, F.M.; Finnerup, N.B.; Jensen, M.P.; Mercier, C.; Richards, J.S.; Wrigley, P.; Soler, D.; Kramer, J.L.K. Meta-Analysis
of Placebo Responses in Central Neuropathic Pain: Impact of Subject, Study, and Pain Characteristics. Pain 2016, 157, 530–540.
[CrossRef] [PubMed]
149. Castelnuovo, G.; Giusti, E.M.; Manzoni, G.M.; Saviola, D.; Gabrielli, S.; Lacerenza, M.; Pietrabissa, G.; Cattivelli, R.;
Spatola, C.A.M.; Rossi, A.; et al. What Is the Role of the Placebo Effect for Pain Relief in Neurorehabilitation? Clinical Implications
from the Italian Consensus Conference on Pain in Neurorehabilitation. Front. Neurol. 2018, 9, 310. [CrossRef] [PubMed]
150. Cepeda, M.S.; Berlin, J.A.; Gao, C.Y.; Wiegand, F.; Wada, D.R. Placebo Response Changes Depending on the Neuropathic Pain
Syndrome: Results of a Systematic Review and Meta-Analysis. Pain Med. 2012, 13, 575–595. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2022, 23, 4196 21 of 22

151. Häuser, W.; Sarzi-Puttini, P.; Tölle, T.R.; Wolfe, F. Placebo and Nocebo Responses in Randomised Controlled Trials of Drugs
Applying for Approval for Fibromyalgia Syndrome Treatment: Systematic Review and Meta-Analysis. Clin. Exp. Rheumatol. 2012,
30, 78–87. [PubMed]
152. Macedo, A.; Baños, J.-E.; Farré, M. Placebo Response in the Prophylaxis of Migraine: A Meta-Analysis. Eur. J. Pain 2008, 12, 68–75.
[CrossRef] [PubMed]
153. Schneider, T.; Luethi, J.; Mauermann, E.; Bandschapp, O.; Ruppen, W. Pain Response to Open Label Placebo in Induced Acute
Pain in Healthy Adult Males. Anesthesiology 2020, 132, 571–580. [CrossRef] [PubMed]
154. Damien, J.; Colloca, L.; Bellei-Rodriguez, C.-É.; Marchand, S. Pain Modulation: From Conditioned Pain Modulation to Placebo
and Nocebo Effects in Experimental and Clinical Pain. Int. Rev. Neurobiol. 2018, 139, 255–296. [CrossRef]
155. Klinger, R.; Stuhlreyer, J.; Schwartz, M.; Schmitz, J.; Colloca, L. Clinical Use of Placebo Effects in Patients with Pain Disorders.
Int. Rev. Neurobiol. 2018, 139, 107–128. [CrossRef] [PubMed]
156. Darnall, B.D.; Colloca, L. Optimizing Placebo and Minimizing Nocebo to Reduce Pain, Catastrophizing, and Opioid Use:
A Review of the Science and an Evidence-Informed Clinical Toolkit. In International Review of Neurobiology; Elsevier: Amsterdam,
The Netherlands, 2018; Volume 139, pp. 129–157. ISBN 978-0-12-815416-8.
157. Diederich, N.J.; Goetz, C.G. The Placebo Treatments in Neurosciences: New Insights from Clinical and Neuroimaging Studies.
Neurology 2008, 71, 677–684. [CrossRef] [PubMed]
158. Kim, J.Y.; Chung, E.J.; Lee, W.Y.; Shin, H.Y.; Lee, G.H.; Choe, Y.-S.; Choi, Y.; Kim, B.J. Therapeutic Effect of Repetitive Transcranial
Magnetic Stimulation in Parkinson’s Disease: Analysis of [11C] Raclopride PET Study. Mov. Disord. 2008, 23, 207–211. [CrossRef]
[PubMed]
159. Ko, J.H.; Feigin, A.; Mattis, P.J.; Tang, C.C.; Ma, Y.; Dhawan, V.; During, M.J.; Kaplitt, M.G.; Eidelberg, D. Network Modulation
Following Sham Surgery in Parkinson’s Disease. J. Clin. Investig. 2014, 124, 3656–3666. [CrossRef] [PubMed]
160. Schmidt, L.; Braun, E.K.; Wager, T.D.; Shohamy, D. Mind Matters: Placebo Enhances Reward Learning in Parkinson’s Disease.
Nat. Neurosci. 2014, 17, 1793–1797. [CrossRef]
161. Espay, A.J.; Norris, M.M.; Eliassen, J.C.; Dwivedi, A.; Smith, M.S.; Banks, C.; Allendorfer, J.B.; Lang, A.E.; Fleck, D.E.;
Linke, M.J.; et al. Placebo Effect of Medication Cost in Parkinson Disease: A Randomized Double-Blind Study. Neurology
2015, 84, 794–802. [CrossRef] [PubMed]
162. Shetty, N.; Friedman, J.H.; Kieburtz, K.; Marshall, F.J.; Oakes, D. The Placebo Response in Parkinson’s Disease. Parkinson Study
Group. Clin. Neuropharmacol. 1999, 22, 207–212. [PubMed]
163. Diamond, S.G.; Markham, C.H.; Treciokas, L.J. Double-Blind Trial of Pergolide for Parkinson’s Disease. Neurology 1985,
35, 291–295. [CrossRef] [PubMed]
164. Goetz, C.G.; Leurgans, S.; Raman, R.; Stebbins, G.T. Objective Changes in Motor Function during Placebo Treatment in PD.
Neurology 2000, 54, 710–714. [CrossRef] [PubMed]
165. Goetz, C.G.; Wuu, J.; McDermott, M.P.; Adler, C.H.; Fahn, S.; Freed, C.R.; Hauser, R.A.; Olanow, W.C.; Shoulson, I.;
Tandon, P.K.; et al. Placebo Response in Parkinson’s Disease: Comparisons among 11 Trials Covering Medical and Surgical
Interventions. Mov. Disord. 2008, 23, 690–699. [CrossRef] [PubMed]
166. Goetz, C.G.; Leurgans, S.; Raman, R. Parkinson Study Group Placebo-Associated Improvements in Motor Function: Comparison
of Subjective and Objective Sections of the UPDRS in Early Parkinson’s Disease. Mov. Disord. 2002, 17, 283–288. [CrossRef]
[PubMed]
167. Benedetti, F.; Frisaldi, E.; Carlino, E.; Giudetti, L.; Pampallona, A.; Zibetti, M.; Lanotte, M.; Lopiano, L. Teaching Neurons to
Respond to Placebos. J. Physiol. 2016, 594, 5647–5660. [CrossRef] [PubMed]
168. Dumitriu, A.; Popescu, B.O. Placebo Effects in Neurological Diseases. J. Med. Life 2010, 3, 114–121.
169. Oken, B.S. Placebo Effects: Clinical Aspects and Neurobiology. Brain 2008, 131, 2812–2823. [CrossRef] [PubMed]
170. Beyenburg, S.; Stavem, K.; Schmidt, D. Placebo-Corrected Efficacy of Modern Antiepileptic Drugs for Refractory Epilepsy:
Systematic Review and Meta-Analysis. Epilepsia 2010, 51, 7–26. [CrossRef] [PubMed]
171. Marson, A.G.; Kadir, Z.A.; Chadwick, D.W. New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability.
BMJ 1996, 313, 1169–1174. [CrossRef] [PubMed]
172. Guekht, A.B.; Korczyn, A.D.; Bondareva, I.B.; Gusev, E.I. Placebo Responses in Randomized Trials of Antiepileptic Drugs.
Epilepsy Behav. 2010, 17, 64–69. [CrossRef]
173. Brown, W.A. Placebo as a Treatment for Depression. Neuropsychopharmacology 1994, 10, 265–269. [CrossRef] [PubMed]
174. Robinson, L.A.; Berman, J.S.; Neimeyer, R.A. Psychotherapy for the Treatment of Depression: A Comprehensive Review of
Controlled Outcome Research. Psychol. Bull. 1990, 108, 30–49. [CrossRef]
175. Rief, W.; Nestoriuc, Y.; Weiss, S.; Welzel, E.; Barsky, A.J.; Hofmann, S.G. Meta-Analysis of the Placebo Response in Antidepressant
Trials. J. Affect. Disord. 2009, 118, 1–8. [CrossRef]
176. Mavissakalian, M. The Placebo Effect in Agoraphobia. J. Nerv. Ment. Dis. 1987, 175, 95–99. [CrossRef]
177. Mellergård, M.; Rosenberg, N.K. Patterns of Response during Placebo Treatment of Panic Disorder. Acta Psychiatry Scand. 1990,
81, 340–344. [CrossRef]
178. Piercy, M.A.; Sramek, J.J.; Kurtz, N.M.; Cutler, N.R. Placebo Response in Anxiety Disorders. Ann. Pharmacother. 1996,
30, 1013–1019. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2022, 23, 4196 22 of 22

179. Huppert, J.D.; Schultz, L.T.; Foa, E.B.; Barlow, D.H.; Davidson, J.R.T.; Gorman, J.M.; Shear, M.K.; Simpson, H.B.; Woods, S.W.
Differential Response to Placebo among Patients with Social Phobia, Panic Disorder, and Obsessive-Compulsive Disorder. Am. J.
Psychiatry 2004, 161, 1485–1487. [CrossRef] [PubMed]
180. Khan, A.; Kolts, R.L.; Rapaport, M.H.; Krishnan, K.R.R.; Brodhead, A.E.; Browns, W.A. Magnitude of Placebo Response and
Drug-Placebo Differences across Psychiatric Disorders. Psychol. Med. 2005, 35, 743–749. [CrossRef] [PubMed]
181. Stein, D.J.; Baldwin, D.S.; Dolberg, O.T.; Despiegel, N.; Bandelow, B. Which Factors Predict Placebo Response in Anxiety Disorders
and Major Depression? An Analysis of Placebo-Controlled Studies of Escitalopram. J. Clin. Psychiatry 2006, 67, 1741–1746.
[CrossRef] [PubMed]
182. Pecknold, J.C.; Swinson, R.P.; Kuch, K.; Lewis, C.P. Alprazolam in Panic Disorder and Agoraphobia: Results from a Multicenter
Trial. III. Discontinuation Effects. Arch. Gen. Psychiatry 1988, 45, 429–436. [CrossRef]
183. Ballenger, J.C.; Burrows, G.D.; DuPont, R.L.; Lesser, I.M.; Noyes, R.; Pecknold, J.C.; Rifkin, A.; Swinson, R.P. Alprazolam in Panic
Disorder and Agoraphobia: Results from a Multicenter Trial. I. Efficacy in Short-Term Treatment. Arch. Gen. Psychiatry 1988,
45, 413–422. [CrossRef]
184. Weiss, R.D.; O’malley, S.S.; Hosking, J.D.; Locastro, J.S.; Swift, R.; COMBINE Study Research Group. Do Patients with Alcohol
Dependence Respond to Placebo? Results from the COMBINE Study. J. Stud. Alcohol Drugs 2008, 69, 878–884. [CrossRef]
185. Ader, R.; Cohen, N. Behaviorally Conditioned Immunosuppression and Murine Systemic Lupus Erythematosus. Science 1982,
215, 1534–1536. [CrossRef]
186. Klosterhalfen, W.; Klosterhalfen, S. Pavlovian Conditioning of Immunosuppression Modifies Adjuvant Arthritis in Rats.
Behav. Neurosci. 1983, 97, 663–666. [CrossRef]
187. Kemeny, M.E.; Rosenwasser, L.J.; Panettieri, R.A.; Rose, R.M.; Berg-Smith, S.M.; Kline, J.N. Placebo Response in Asthma: A Robust
and Objective Phenomenon. J. Allergy Clin. Immunol. 2007, 119, 1375–1381. [CrossRef]
188. Kaptchuk, T.J.; Kelley, J.M.; Deykin, A.; Wayne, P.M.; Lasagna, L.C.; Epstein, I.O.; Kirsch, I.; Wechsler, M.E. Do “Placebo
Responders” Exist? Contemp. Clin. Trials 2008, 29, 587–595. [CrossRef] [PubMed]
189. Olness, K.; Ader, R. Conditioning as an Adjunct in the Pharmacotherapy of Lupus Erythematosus. J. Dev. Behav. Pediatr. 1992,
13, 124–125. [CrossRef] [PubMed]
190. Vits, S.; Cesko, E.; Benson, S.; Rueckert, A.; Hillen, U.; Schadendorf, D.; Schedlowski, M. Cognitive Factors Mediate Placebo
Responses in Patients with House Dust Mite Allergy. PLoS ONE 2013, 8, e79576. [CrossRef] [PubMed]
191. Meissner, K.; Bingel, U.; Colloca, L.; Wager, T.D.; Watson, A.; Flaten, M.A. The Placebo Effect: Advances from Different
Methodological Approaches. J. Neurosci. 2011, 31, 16117–16124. [CrossRef]
192. Vits, S.; Cesko, E.; Enck, P.; Hillen, U.; Schadendorf, D.; Schedlowski, M. Behavioural Conditioning as the Mediator of Placebo
Responses in the Immune System. Philos. Trans. R Soc. Lond. B Biol. Sci. 2011, 366, 1799–1807. [CrossRef]
193. Schaefer, M.; Harke, R.; Denke, C. Open-Label Placebos Improve Symptoms in Allergic Rhinitis: A Randomized Controlled Trial.
Psychother. Psychosom. 2016, 85, 373–374. [CrossRef]
194. May, O.; Hansen, N.C. Comparison of Terbutaline, Isotonic Saline, Ambient Air and Non-Treatment in Patients with Reversible
Chronic Airway Obstruction. Eur. Respir. J. 1988, 1, 527–530.
195. Isenberg, S.A.; Lehrer, P.M.; Hochron, S. The Effects of Suggestion on Airways of Asthmatic Subjects Breathing Room Air as a
Suggested Bronchoconstrictor and Bronchodilator. J. Psychosom. Res. 1992, 36, 769–776. [CrossRef]
196. Wechsler, M.E.; Kelley, J.M.; Boyd, I.O.E.; Dutile, S.; Marigowda, G.; Kirsch, I.; Israel, E.; Kaptchuk, T.J. Active Albuterol or
Placebo, Sham Acupuncture, or No Intervention in Asthma. N. Engl. J. Med. 2011, 365, 119–126. [CrossRef]